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Abstract 
N-Palmitoylethanolamide (PEA) is an endogenous N-acylethanolamine, 
first identified in lipid extracts from brain, liver, and muscle of rat and 
guinea pig. PEA is formed “on demand” from membrane phospholipids 
and it is gaining ever-increasing interest not only for its anti-
inflammatory and analgesic effects mediated by peroxisome-proliferator 
activated receptor (PPAR)-α, but also for its novel metabolic effects. 
Overweight and obesity are defined as abnormal or excessive fat 
accumulation that may impair health. Main consequence of obesity is 
cardiovascular disease (CVD). The sum of the risk factors that 
predisposes to CVD goes by the name of “metabolic syndrome” (MetS). 
Hypertension is an important hallmark of MetS and a common cause of 
kidney disease. 
In the first part of this thesis, we investigated the mechanisms 
underpinning PEA blood pressure lowering effect, exploring the 
contribution of epoxyeicosatrienoic acids (EETs), CYP-dependent 
arachidonic acid (AA) metabolites, as endothelium derived 
hyperpolarizing factors (EDHF), and renin-angiotensin system (RAS) 
modulation. To achieve this aim, SHR and Wistar-Kyoto normotensive 
(WKY) rats were treated with PEA (30 mg/kg/day, s.c.) for five weeks. 
Functional evaluations on mesenteric bed were performed to analyze 
EDHF mediated vasodilation. Moreover, mesenteric bed and carotid were 
harvested to measure the soluble epoxide hydrolase (sEH), which is the 
enzyme responsible for EETs degradation in their corresponding inactive 
diols. Effect of PEA on RAS modulation was investigated by analyzing 
angiotensin converting enzyme (ACE) and angiotensin receptor (AT)1 
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expression. We showed that EDHF-mediated dilation in response to 
acetylcholine (Ach) was increased in mesenteric beds of PEA-treated 
SHR. Interestingly, in both vascular tissues, PEA significantly decreased 
the sEH protein level, accompanied by a reduced serum concentration of 
its metabolite 14-15 dihydroxyeicosatrienoic acid (DHET), implying a 
reduction in EET hydrolysis. Moreover, PEA treatment down-regulated 
AT1 and ACE expression, indicating a reduction in Ang II-mediated 
effects. Our data clearly demonstrate the involvement of EETs and RAS 
in the blood pressure lowering effect of PEA. 
The relationship between obesity, insulin-resistance (IR) type 2 diabetes 
mellitus (T2DM) and MetS is well known. IR is defined as an inefficient 
glucose uptake and utilization in peripheral tissues in response to insulin 
stimulation. IR in the prediabetes stage is a feature of glucose intolerance, 
which includes impaired fasting glucose and/or impaired glucose 
tolerance. When insulin binds to its transmembrane receptor (InsR), 
promotes its autophosphorylation (pInsR). Activated pInsR recruits 
insulin receptor substrate (IRS), leading to insulin signaling cascade. A 
potential link between inflammation and IR has been shown. Indeed, 
obesity is characterized by chronic low grade inflammation, where the 
release of adipose tissue-derived cytokines can block insulin action and 
cause systemic IR. In fact, serum tumor necrosis factor (TNF)-α and 
interleukin (IL)-6 are significantly increased in serum from obese 
patients. All cytokines induce IRS1 protein degradation, which 
suppresses insulin signaling pathway and subsequently suppresses 
glucose transporter (GLUT) translocation and glycogen synthesis, 
contributing to IR and hyperglycemia. Our study was focused on the 
pharmacological effect of PEA in an animal model of diet-induced 
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obesity (DIO), feeding mice with a high-fat diet (HFD), and on the 
mechanisms by which this lipid mediator could modulate the storage and 
availability of energy sources, restoring lipid/glucose homeostasis. To 
achieve this aim, mice were fed a standard chow diet (STD group) or 
HFD (DIO group). After twelve weeks, both STD or HFD mice were 
treated with PEA (30 mg/kg/day, o.s.) for ten weeks. At the end of the 
experimental period, body parameters were determined, and serum and 
tissues collected for following determinations. Interestingly, PEA caused 
a reduction in body weight and fat mass, improved glucose tolerance and 
prevented IR, induced by HFD feeding. Moreover, PEA restored the 
alterations of serum biochemical and inflammatory parameters, inducing 
a marked reduction of ALT, AST, cholesterol, and pro-inflammatory 
cytokines, such as TNF-α, IL-1 and monocyte chemoattractant protein 
(MCP)-1. PEA also normalized metabolic hormone levels and restored 
insulin sensitivity. At hepatic level, PEA treatment significantly induced 
an increase in the activation AMPK/ACC pathway, stimulating fatty acid 
oxidation, compromised in obese mice. To evaluate tissue insulin-
sensitivity, we determined the hepatic expression of the InsR, whose 
expression decreased in liver of DIO mice compared to that of STD 
animals, and increased in PEA-treated mice. Then, we evaluated the 
effectiveness of hepatic insulin signaling through the evaluation of InsR 
and Akt phosphorylated state and the expression of GLUT-2. PEA 
treatment restored insulin signaling. The protective effect of PEA was 
strengthened by the evaluation of hepatic IL-6 and TNF-α, whose 
transcription, upregulated by HFD feeding, was reduced. To address the 
direct effect of PEA on hepatic insulin-sensitivity, we evaluated the 
restoration of insulin signaling, altered by the induction of IR, in HepG2 
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cells, a human hepatocarcinoma cell line. Therefore, we demonstrated in 
vitro that PEA increased the phosphorylation of Akt in insulin resistant 
cells, following insulin stimulation. PEA was also able to modulate 
glucose homeostasis at hypothalamic level. Therefore, we examined 
neuronal activation at the arcuate (ARC) and ventromedial (VMH) 
nuclei, evaluating c-fos immunostaining. In the ARC nucleus of DIO 
mice, a decrease in c-fos labeling was found. Interestingly, in the PEA-
treated DIO group, a trend of c-fos labeling increase was evidenced. 
Consistently, in the VHM of DIO mice a significant decrease in the 
neuronal activation was shown compared to STD mice, although, no 
differences were found between DIO and PEA-treated DIO mice. The 
involvement of the hypothalamic control of glucose homeostasis by PEA 
was confirmed in in vitro experiments, using human SH-SY5Y 
neuroblastoma cell line. When insulin-resistant cells were treated with 
PEA, the re-stimulation with insulin showed a restoration of Akt 
phosphorylation, and therefore of insulin-sensitivity. These findings show 
that this acylethanolamide also displays a central effect on glucose 
homeostasis, reducing neuronal IR. Our data strengthened evidence on 
the metabolic activity of PEA, through the involvement of central and 
peripheral mechanisms. PEA clearly ameliorates glucose-tolerance and 
insulin-sensitivity, indicating its therapeutic potential for the treatment of 
metabolic dysfunctions associated to obesity, such as IR and T2DM. 
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Introduction 
Fatty acylethanolamides (FAEs), generally referred as N-
acylethanolamines (NAEs), are a group of endogenous lipid mediators, 
derived from different long-chain fatty acids, and synthesized in 
various mammalian tissues [1, 2]. NAEs have increasingly received 
attention due to their numerous biological activities [3]. NAEs include 
arachidonoylethanolamide (N-arachidonoylethanolamine, anandamide, 
AEA), stearoylethanolamide (N-stearoylethanolamine, SEA), 
oleoylethanolamide (N-oleoylethanolamine, OEA), and 
palmitoylethanolamide (N-palmitoylethanolamine, PEA) (figure 1) [4, 
5]. 
 
 
Figure 1. Chemical structures of representative NAEs. 
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The most known NAE is AEA, an endogenous eicosanoid derivative 
that was the first endocannabinoid identified, as ligand of cannabinoid 
receptors CB1 and CB2 [6] It appears as a relevant modulator of 
several physiological functions not only in the central and autonomic 
nervous system, but also in immune system, endocrine network, 
gastrointestinal tract and reproductive system [7]. It is well known that 
AEA is able to produce analgesia, control motor activity, to reduce 
emesis, to stimulate appetite, to induce hypothermia and also to 
present anti-proliferative effects [8, 9]. Its activities and effects seems 
also mediated by the activation of the endovanilloid receptor (transient 
receptor potential vanilloid type1, TRPV1) [10]. However, AEA is a 
minor component in most animal tissues compared with other NAEs, 
such as SEA, OEA and PEA [6, 11]. These NAEs, except AEA, do not 
bind to cannabinoid receptors, but exert their biological actions 
through several other receptors. Among these, PEA is endogenously 
produced in every mammalian cells at low levels. Their production is 
“on demand” from membrane phospholipids when there is cellular 
injury and inflammation [12]. 
PEA has been studied extensively for its anti-inflammatory, analgesic, 
and neuroprotective actions, especially in models of pain [13, 14]. In 
the past, PEA was considered a CB2 agonist [15], but other study 
carried out by Lo Verme et al. [16] showed no effect of PEA in CB2 
knockout mice. To date, it is well known that PEA actions are 
mediated by peroxisome proliferator-activated receptor (PPAR)-α [16, 
17] and GPR55 [18]. PPAR-α is a ubiquitous transcription factor, 
activated by endogenous fatty acid derivatives, including PEA and 
OEA [16], affecting transcription of numerous genes involved in lipid 
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metabolism and inflammation. PEA efficacy in inducing anti-
inflammatory and anti-nociceptive activities, are mediated by PPAR-α 
[13, 16]. 
Overweight and obesity result from an imbalance of food intake, basal 
metabolism, and energy expenditure. Main consequence of obesity is 
cardiovascular disease (CVD) [19]. A great portion of the CVD 
resulting from obesity is mediated by type 2 diabetes mellitus 
(T2DM). However, obesity is accompanied by several other risk 
factors for CVD. The sum of the risk factors that predisposes to CVD 
goes by the name of “metabolic syndrome” (MetS). 
Since hypertension and obesity are two of five risk factors associated 
with the onset of MetS, we determined the pharmacological effect of 
PEA in a genetic animal model of hypertension, i.e. spontaneously 
hypertensive rats (SHR), and in an animal model of diet-induced 
obesity (DIO), feeding mice with a high-fat diet (HFD). These 
preclinical models have allowed us to investigate the mechanisms by 
which this lipid mediator could modulate functions involved in the 
storage and availability of energy sources, restoring lipid/glucose 
homeostasis and its capability in limiting many pathological features 
of MetS. 
8 
 
1. PEA: origin, structure and activity 
PEA is a fully saturated, bioactive, endogenous NAE, identified a 
century ago in lipid extracts from brain, liver, and muscle of rat and 
guinea pig [20]. Subsequently, it was shown to be present in other 
organs in higher levels than AEA [21, 22] where is synthesized “on 
demand” from membrane phospholipids [12]. PEA has long been 
known to have immunosuppressive [23], analgesic [24], 
neuroprotective [25] and antioxidant [26] properties. The anti-
inflammatory effect of PEA and interaction upon PPAR-α is well 
documented. This receptor is distributed at peripheral and central level 
and functions as a regulator of fatty acid oxidation, lipid metabolism, 
and inflammation affecting transcription of numerous genes [27, 28]. 
It is generally accepted that PEA is principally biosynthesized in 
animal tissues from phosphatidylethanolamine (PE) by two sequential 
enzyme reactions [1-3]. As depicted in figure 2, the first reaction is the 
transfer of an acyl-group (palmitic acid) from the sn-1 position of 
phosphatidylcholine (PC) to PE by an N-acyltransferase (NAT), 
resulting in the generation of N-acyl- PE (NAPE) (1) [29]. 
Subsequently, PEA is released from NAPE by a phosphodiesterase of 
phospholipase D (NAPE-PLD) (2) [30]. PEA is rapidly catabolized by 
fatty acid amide hydrolase (FAAH) to palmitic acid and ethanolamine 
(3) [31, 32] or N-acylethanolamine-hydrolyzing acid amidase (NAAA) 
in inflammatory status [33]. 
9 
 
 
Figure 2. PEA: biosynthetic and degradative pathways of PEA. 
 
In particular, PEA, being a lipophilic molecule, can flip throughout the 
phospholipid bilayer of the plasma membrane [34] and then 
transported by fatty acid binding proteins or heat shock proteins to 
degrading enzymes or to target molecules such as PPAR-α [35] and 
vanilloid receptor [36]. 
 
1.1. Peroxisome proliferator-activated receptors (PPARs): PPAR-α 
and PEA 
PPARs are ligand-activated transcription factors belonging to the 
nuclear receptor superfamily. Three different isoforms (α, β/δ, and γ) 
(figure 3) have been described, all of which display distinct 
physiological functions dependent on their differential ligand 
activation profiles and tissue distribution [37]. 
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Figure 3. Tridimensional structure of different isoforms of PPARs. 
 
PPARs are regulators of gene networks, which mainly control pain and 
inflammation, by switching off the nuclear factor-кB (NF-кB) 
signaling cascade, leading to the synthesis modulation of pro-
inflammatory mediators [38]. In particular, PPAR-α and PPAR-γ 
receptor subtypes have been reported to regulate in vivo and in vitro 
inflammatory responses [39, 40]. 
Different type of fatty acids (FAs) binding PPAR induce a 
conformational change of nuclear receptors, triggering the 
transcription of specific genes including those encoding for various 
metabolic and cellular processes such as FA β-oxidation and 
adipogenesis, thus to be considered key mediators of lipid homeostasis 
[41]. Drugs able to activate these receptors, modulating the lipid and 
glucose metabolism, constitute a viable therapy for patients with 
dyslipidemia, T2DM, atherosclerosis and cardiovascular diseases [42, 
43]. 
The tissue distribution of PPAR-α varies: PPAR-α expression has been 
demonstrated in brain [44] and spinal cord [44-46] liver, kidney heart 
and brown adipose tissue [47]. Evidence has shown its importance in 
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the regulation of lipid metabolism, obesity [48] behind its capability to 
modulate inflammation. 
The first indication for a role of PPAR-α in modulating inflammation 
was demonstrated by that the ability of leukotriene B4, a potent 
chemotactic inflammatory eicosanoid, to bind PPAR-α and induce 
gene transcription of enzymes involved in ω- and β-oxidation 
pathways that metabolize leukotriene B4. Moreover, mutant mice 
lacking PPAR-α (PPAR-α-/-) showed a prolonged inflammatory 
response when challenged with leukotriene B4 or arachidonic acid 
(AA) [49]. The inhibition of pro-inflammatory factors, such as 
interleukin (IL)-6 and prostaglandins, also participate in the PPAR-α-
mediated control of inflammation, probably through the suppression of 
nuclear factor kappa beta (NF-кB) activity [50]. 
It has been postulated that activation of PPAR-α by nonsteroidal anti-
inflammatory agents contributes to the anti-inflammatory, anti-pyretic, 
and analgesic properties of these drugs through stimulation of 
oxidative pathways involved in the catabolism of eicosanoids [42]. 
Numerous data suggest that PEA can be considered an endogenous 
activator of PPAR-α. PEA interacts with this receptor to inhibit 
inflammatory response with a potency comparable with that of the 
synthetic PPAR-α agonist GW7647, without activating PPAR-β/δ or 
PPAR-γ [16, 51]. More recently, we have identified the involvement 
of PPAR-α in PEA protective effect against neurotoxicity and 
endoplasmic reticulum stress both in vivo and in vitro models [52]. 
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1.2. Mechanisms of action of PEA 
Previously, it was suggested that PEA was a CB2 agonist [15]. 
Afterwards, Lo Verme et al. [16] showed that PEA had no effect in 
CB2 knockout mice. Now, it is well-known that the main PEA 
pharmacological effects are mediated by PPAR-α activation [13, 46, 
51]. Initially identified as a receptor for peroxisome-stimulating 
plasticizers in the liver, PPAR-α is a ubiquitous transcription factor, 
activated by various endogenous fatty acid derivatives, including PEA 
and its analog OEA. 
It was found that PEA could potentiate the effect of AEA on CB or 
TRPV1 [53, 54]. This so-called “entourage effect” could be mediated 
by PEA competitive inhibition of AEA hydrolysis on FAAH, leading 
to an increase in AEA levels and its binding to CB1 [55] (figure 4A) 
and/or direct allosteric effect of PEA on TRPV1, increasing AEA 
affinity to this receptor, and inducing later TRPV1 desensitization [56, 
57] (figure 4B). Through a PPAR-α dependent non-genomic 
mechanism, PEA increases the gating properties of calcium-activated 
intermediate (IKCa) and big-conductance potassium (BKCa) channels, 
resulting in a fast reduction of neuronal firing [51] Moreover, PPAR-α 
activation, through a genomic mechanism, increases the expression of 
steroidogenic acute regulatory protein (StAR) and cytochrome P450 
side-chain cleavage (CYP450scc), involved in cholesterol transfer into 
the mitochondria and its metabolism in pregnanolone, respectively. 
The resulting increase in allopregnanolone levels leads to a positive 
allosteric activation of -aminobutyric acid (GABA) (A) receptors, an 
increase in Cl−currents and a reinforcing effect on the reduction of 
neuronal firing. PEA anti-inflammatory effect appears to be related to 
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a cytoplasmic complex, that reduces NF-кB transcription activity, 
dampening the transcription of pro-inflammatory gene (figure 4C) 
[13]. 
 
 
Figure 4. Mechanisms of action of PEA: effect entourage through competitive inhibition of 
the metabolism of AEA by FAAH (A); allosteric activity on TRPV1 and its desensitization 
(B); Genomic and not genomic mechanisms dependent on PPAR-α (C). 
 
Furthermore, PEA is reported to have affinity for orphan receptors 
such as GPR55, a G-protein coupled receptor (GPCR) [58]. It has been 
described as a type 3 cannabinoid receptor (CB3) due to its ability to 
detect endocannabinoids and may play a role in the endocannabinoid 
lipid sensing system [6]. Indeed, GPR55 activation has been suggested 
to account for some of the non-CB1, non-CB2 effects reported for 
certain cannabinoid ligands [59]. This receptor has been associated 
with several physiological roles in inflammation [60], osteogenesis 
[61], insulin secretion and glucose homeostasis [62]. Moreover, it has 
been demonstrated that PEA could also bind GPR119 [63]. This 
receptor is expressed at particularly high levels in the gut and also 
found in immune cells. Initially considered a “third” endocannabinoid 
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receptor, despite sharing little homology with CBs, it has been linked 
to inflammatory processes as well [64]. Previously, Overton and 
colleagues [63] have shown that OEA could be an agonist for 
GPR119, while PEA and AEA displayed very weak affinity. This 
receptor is particularly known for its involvement in glucagon-like-
protein (GLP)-1 receptor secretion from entero-endocrine cells in the 
gut and hence glucose homeostasis [65]. 
 
1.3. Pharmacological activity of PEA 
In addition to the anti-inflammatory activity, PEA inhibits food intake 
[66], reduces the gastrointestinal motility [67], cell proliferation [68] 
and protects the vascular endothelium in case of myocardial ischemia 
[69]. First experiments led in the 50s and recent studies have 
demonstrated that PEA inhibits the degranulation of mast cells [70] 
and pulmonary inflammation in the mouse [71]. Ross and coll. [72] 
have shown the ability of PEA to reduce the production of nitric oxide 
(NO) in macrophages. 
Several mechanisms of action of PEA have been proposed in a model 
of acute inflammation (carrageenan-induced paw edema). Animals 
treated for three days with the PEA (10 mg/kg/day os) showed a 
significant reduction in the levels of inducible nitric oxide synthase 
(iNOS) and cyclooxygenase (COX)-2, suggesting a genomic 
mechanism similar to that of the steroid anti-inflammatory drugs [73]; 
however, various studies show that PEA quickly reduces the acute 
inflammation as well [16, 73], suggesting the involvement of a not 
genomic mechanism. 
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Since the analgesia produced by this acylethanolamide is rapid and 
precedes the action of anti-inflammatory substances, on the basis of 
the studies performed by Calignano and coll. [24], it was assumed that 
the endogenous PEA in basal conditions would be involved in the 
regulation of pain sensitivity. The analgesic effect of endogenous 
acylethanolamines may be mediated by the modulation of the 
conductance of specific ion channels [74]. 
Sasso et al. [75] have also shown that the analgesic effects of PEA are 
in part due to the induction of de novo synthesis of neurosteroids 
exploiting an acute and a chronic animal model of pain: the assay of 
formalin and carrageenan-induced paw edema, respectively. The 
administration of formalin or carrageenan causes a decrease at spinal 
level of two proteins involved in the genesis of neurosteroids: 
CYP450scc and StAR. 
The reduction of the expression of CYP450scc, StAR and the 
consequent reduction of the levels of allopregnanolone can be 
prevented through treatment with PEA. This effect is also blocked by 
inhibitors of de novo synthesis of neurosteroids, such as for example 
aminoglutethimide and finasteride. These results demonstrate that 
antinociceptive effects of PEA, are not only related to the quick action 
of damping of neuronal firing, but also to the prolonged long lasting 
action supported by neurosteroid synthesis. 
A role for PPAR-α has been addressed in cardiovascular system and 
its ligands have been shown to protect against inflammatory damage 
especially resulting from angiotensin II hypertension. Our recent study 
demonstrates that PEA significantly reduced blood pressure in SHR 
and limited kidney damage to high perfusion pressure [76]. Recently, 
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the metabolic activity of PEA has been reviewed [13], highlighting its 
strong link to PPAR-α, in addition to its capability to induce profound 
anti-inflammatory and anti-nociceptive effects [16]. In fact, our recent 
study demonstrates anorexic and fat-losing effects of a chronic 
treatment with PEA in ovariectomized (OVX) obese rats [77]. 
It has been shown that the activation of PPAR-α mediated the anorexic 
effect of AEs, and in particular of OEA, on feeding behavior and 
weight loss [78, 79]. PEA, as OEA, binds PPAR-α, but is unable to 
exert on food intake and lipolysis, effects similar to those of OEA, as 
shown by Rodriguez de Fonseca [78], possibly because of its lower 
potency. Administration of PEA in rats and mice induced a rapid 
decrease in food intake [80]. The anorectic action of exogenous PEA 
is mediated by the activation of the transcription factor PPAR-α in the 
small intestine [80, 81]. PEA, as OEA, has an endogenous anorectic 
role. In rats, at small intestine level, transient overexpression of 
NAPE-PDL resulted in decreased food intake in the same time 
window where increased intestinal levels of OEA and PEA were also 
observed [82]. The activity of NAPE-PLD changes: being low during 
fasting and high after re-feeding as are the NAPE precursors for OEA 
and PEA. This data suggests that these intestinal changes in tissue 
levels are regulated through formation of NAPE precursors and 
NAPE-PLD activity, but not through changes in NAE degradation 
[83]. Therefore, the activity of the NAPE-synthesizing enzyme NAT 
may play a central role in regulating the intestinal levels of the 
anorectic NAEs. Furthermore, in mouse, intestinal level of OEA and 
PEA seems to decrease in response to high-fat feeding. It was 
speculated that PEA and other chain fatty acids, are biosensors of 
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dietary fat. The decreased intestinal level of OEA and PEA may 
contribute to hyperphagic effect of prolonged intake of dietary fat [11]. 
Dietary fat is digested by hydrolysis of triacylglycerol to 2-
monoacylglycerol (2-MAG) and free fatty acids, which are absorbed 
and used for triacylglycerol synthesis and chylomicron [84, 85]. The 
HFD provides oleic, palmitic and linoleic acids, which are taken up 
into the enterocyte probably via the membrane-protein CD36 and 
incorporated in NAPE (figure 5). These fatty acids increase intestinal 
levels of OEA and PEA. On the other hand, the prolonged intake of 
fat, which leads to increases in fatty acids and 2-MAG in the lumen, 
via unknown receptor, results in down regulation of the activity of 
NAT and thereby decrease in the amount of NAPE species in the 
enterocyte. So, diet rich in palmitic acid induces a decrease of OEA 
and PEA, but the decrease in PEA levels is less profound than that of 
OEA because palmitic acid from diet enriches the NAPE precursor 
pool with N-palmitoyl-phosphatidylethanolamine and consequently 
increases PEA. OEA and PEA can activate PPAR-α and bring the 
signal further to the vagus nerve leading to the brain [86]. 
 
 
Figure 5. PEA and OEA as biosensors of dietary fat. 
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1.4. Role of PEA on peripheral or central metabolism 
PPAR-α plays an important metabolic role regulating fatty acid 
oxidation in tissue with a high rate of fatty acid oxidation, such as 
liver, heart and skeletal muscle [27, 87]. All isoforms of PPAR-α were 
shown to reveal specific patterns of localization in several areas of the 
brain [45] and injection of PPAR-α agonist into the hypothalamus was 
shown to induce expression of PPAR-α target genes and reduce food 
intake [88]. Thus PEA, binding and activating PPAR-α, acts both at 
peripheral and central level. As mentioned before, PEA effects have 
been demonstrated to be consistent with the recovery of the 
impairment of leptin receptor signaling at hypothalamic level, 
restoring leptin sensitivity in OVX rats [77]. Furthermore, body 
weight reduction following PEA treatment, together with the reversion 
in leptin resistance, was related to the suppression of food intake by 
hypothalamic modulation of AMP-activated protein kinase (AMPK) 
activity and neuropeptide synthesis. Further the central hypothalamic 
effect of PEA, was supported by a peripheral effect of this 
ethanolamide on white adipose tissue. Indeed PEA, increasing AMPK 
activation in adipose tissue, inhibits pro-inflammatory cytokine 
synthesis. Consequently, with pAMPK increase in adipose tissue, PEA 
restores carnitine palmitoyl transferase (CPT)-1 transcription, 
confirming its role in the lipid catabolic pathways [77]. 
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2. Obesity and related diseases 
Overweight and obesity are defined as abnormal or excessive fat 
accumulation that may impair health, becoming common worldwide 
pathologies. 
A marker of obesity, related to body fat content, is the body mass 
index (BMI) which is a simple index of weight-for-height commonly 
used to classify overweight and obesity in adults. It is defined as a 
person's weight in kilograms divided by the square of his/her height in 
meters (kg/m2). For adults, World Health Organization (WHO) defines 
overweight when BMI is greater than or equal to 25 and obesity when 
BMI is greater than or equal to 30. BMI provides the most useful 
population-level measure of overweight and obesity as it is the same 
for both sexes and for all ages of adults. The best way to estimate 
obesity in clinical practice is to measure waist circumference; indeed, 
an excess of abdominal fat is most closely associated with the 
metabolic risk factors. 
The increase in obesity prevalence is due to two major factors, 
abundant reserve of inexpensive food and sedentary life. Obesity must 
also be recognized as a product of free society in which a multitude of 
food choices and job opportunities are available. Moreover, obesity is 
not a significant public health problem in world area in which 
technological progress is less developed. 
Main consequence of obesity is CVD [19]. A great portion of the CVD 
resulting from obesity is mediated by T2DM, even if several other risk 
factors accompanied CVD. Furthermore, obesity is accompanied by 
other medical complications other than CVD and diabetes; these 
include fatty liver, cholesterol gallstones, sleep apnea, osteoarthritis, 
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kidney disease and polycystic ovary disease [89]. The sum of the risk 
factors that predisposes to CVD goes by the name of MetS. The 
syndrome is a clustering of at least three of the five following 
pathological conditions: 
1) abdominal or central obesity (waist circumference ≥ 102 cm (40 
in) in men or ≥ 88 cm (35 in) in women); 
2) hypertension (≥ 130/85 mg/kg); 
3) elevated fasting plasma glucose (≥ 100 mg/dl); 
4) hypertriglyceridemia (≥ 150 mg/dl); 
5) low high-density lipoprotein (HDL) levels (< 40 mg/dl in men or 
< 50 mg/dl in women). 
In order to better understand the relationship between obesity, diabetes 
and CVD as well as for the development of novel therapeutic 
strategies, animal models that reproduce the etiology, course and 
outcomes of these conditions are required [90]. To reproduce 
metabolic human diseases in animal models, different diet 
compositions have been tested [91]. It has been shown that a high-
sucrose diet exacerbates IR [92] a high-salt or high-fructose diet 
exacerbates hypertension [93], a high-cholesterol diet exacerbates 
atherosclerosis [94] and a short-term HFD results in discrete systolic 
dysfunction [95]. In the scientific literature, it was shown that animals 
consuming diets containing high proportions of fat gained weight 
faster than those on diets containing minimal amounts of fat, because 
more palatable [96]. Foods that are rich in fats have been shown to 
produce increased body weight and diabetes in various strains of mice 
and rats. Some animals show profound increases in their body fat 
content while some are resistant to weight gain with HFD [97]. One of 
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these models that are gaining increasing attention is the DIO model in 
mouse. C57BL/6J mouse is a particularly good model mimicking 
human metabolic derangements that are observed in obesity because 
when fed ad libitum with a HFD, these mice develop obesity, 
hyperinsulinemia, hyperglycemia, and hypertension, but when fed ad 
libitum to chow diet, they remain lean without metabolic abnormalities 
[98]. 
Obesity and its co-morbidities, including T2DM and CVD, are 
associated with a state of chronic low-grade inflammation that can be 
detected both systemically and within specific tissues. An increased 
accumulation of macrophages occurring in obese adipose tissue has 
emerged as a key process in ‘metabolic’ inflammation [99]. Obesity 
and the accompanying MetS are strongly associated with an increase 
of morbidity and mortality in older adults. In the last years, the 
prevalence of obesity has enhanced dramatically, and it has become 
the most common metabolic disease worldwide, leading to a global 
epidemic [100]. The etiology of obesity is complex and multifactorial 
and results from the interaction of genes with the environment, 
lifestyle, and emotional factors. The modern lifestyle is a potent risk 
factor for obesity. Declining physical activity levels and increased 
caloric intake are important environmental factors contributing to 
obesity [101]. The increasing number of overweight and obese 
individuals is a serious public health problem that has implications for 
society and healthcare systems on a global scale. The economic 
consequences of obesity and associated diseases are not limited to high 
medical costs but also include indirect or social costs, such as 
decreased quality of life, problems in social adjustment, lost 
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productivity, disability associated with early retirement, and death 
[102]. 
 
2.1. Components of energy balance system and obesity impairment 
The prime function of the physiological system is to maintain 
homeostasis of energy stores in response to variable access to nutrition 
and demands for energy expenditure. This system has both afferent 
sensing components, and efferent effectors. The afferent arm of this 
system includes several kinds of signals. Some of these reflects short-
term events, such as those related to onset or termination of the meals; 
other ones sense the long-term status of body energy stores. Although 
these long and short-term signals have often been viewed as operating 
independently, it now appears that they functionally overlap. Both 
converge on brain centers, most importantly within the hypothalamus, 
where the signals are integrated, and the direction and intensity of 
efferent responses are determined. The efferent effectors of these 
physiologic systems include those regulating the intensity of hunger 
and subsequent food intake behavior, the energy expenditure, both in 
basal condition and during physical activity, the levels of metabolic 
pivotal circulating hormones, such as insulin and glucocorticoids, and 
other factors that influence the amount of lean and fat mass in the 
body. Some of these signals also regulate processes, such as 
reproduction and growth that are linked to nutritional status (figure 6) 
[103]. 
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Figure 6. Components of the energy balance system. The energy balance system involves 
long-term afferent signals from fat (leptin) and pancreatic cells (insulin) and short-term, meal-
related afferent signals from the gut, including inhibitors of feeding (PYY, GLP-1, and CCK), 
and the stimulator of feeding (ghrelin). These inputs are integrated within the brain. Efferent 
outputs regulate appetite, energy expenditure, hormonal milieu, energy partitioning, and the 
status of reproduction and growth (Flier, 2004). 
 
The hypothalamus is subjected to a continuous flow of signals coming 
either from brain superior areas or periphery, with orexigenic or 
anorexigenic activity, which inform it about energy nutritional 
conditions of the organism [104] and control energy metabolism, 
producing neuropeptides or hormones which can modulate either 
feeding behavior or energy expenditure. The energy expenditure and 
food intake alteration induced by endogenous factors was studied, in 
obese patients. For example, gut hormones play a pivotal role in 
communicating information on nutritional status to hypothalamus 
[105] and comprise pancreatic polypeptide-fold peptides, as GLP-1, 
glucagon, peptide YY (PYY), and pancreatic polypeptide (PP), 
ghrelin, and cholecystokinin (CCK). PYY is an appetite suppressing 
hormone. The PYY secretion pattern has a role in satiety. Circulating 
PYY concentrations are low in fasted state and increase rapidly 
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following a meal with a peak at 1-2 hours and remain elevated for 
several hours. PYY release is increased in proportion to calorie intake 
[106]. PYY has been reported to regulate energy expenditure, delay 
gastric emptying, reduce acid secretion, and inhibit gallbladder 
contraction and pancreatic exocrine secretions [107, 108]. Circulating 
PYY levels are low in obese subjects [109, 110], and higher in patients 
with anorexia nervosa than those of control subjects [111]. 
PP is secreted from PP cells in the pancreatic islets of Langerhans in 
response to a meal. Anorectic effects of PP are thought to be mediated 
directly through the Y4 receptor in the brainstem and hypothalamus 
[112]. Plasma PP levels show diurnal variations: lowest levels are 
observed in the early morning and highest in the evening. The release 
of postprandial PP is biphasic. Circulating PP concentrations increase 
after a meal in proportion to the caloric intake, and the increased levels 
remain high up to 6 hours post-prandially [113]. 
GLP-1 is co-secreted with PYY from the L cells in the intestine in 
response to nutrient ingestion. GLP-1 exerts its effect by activation of 
the GLP-1R to stimulate adenylyl cyclase activity and thereby cAMP 
production [114]. GLP-1R is widely distributed particularly in the 
brain, gastrointestinal tract, and pancreas. Circulating GLP-1 levels 
rise post-prandially and fall in the fasted state. Recent evidence also 
suggests that GLP1 levels rise in anticipation of a meal. [115]. GLP-1 
not only reduces food intake, but also suppresses glucagon secretion 
and delays gastric emptying [116]. The role of glucagon in glucose 
homeostasis is well established; glucagon is produced by alpha cells of 
the pancreatic islets and increases glucose level in response to 
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hypoglycemia. Glucagon enhances the body’s physiological response 
to stress, by increasing energy expenditure [117]. 
Ghrelin was identiﬁed originally as an endogenous ligand for the 
growth hormone secretagogue receptor (GHS-R) in rat stomach [118]. 
Serum ghrelin levels are increased by fasting and decreased by 
refeeding or oral glucose administration, but they are not decreased by 
water ingestion [119]. In rats, ghrelin levels show diurnal pattern, with 
the bimodal peaks occurring before dark and light periods [120]. 
Levels of circulating ghrelin rise pre-prandially and fall rapidly in the 
postprandial period [121]. 
CCK was the ﬁrst gut hormone found to be implicated in appetite 
control. CCK is secreted post-prandially by the I cell of the small 
intestine into circulation with a short plasma half-life of few minutes. 
Plasma CCK levels rise within 15 minutes after meal ingestion [122]. 
Leptin, a 16 kDa adipocyte-derived hormone, is very important in due 
to its role in the regulation of energy balance. Leptin, secreted from 
adipose tissues in proportion to the fat store [123], acts in the 
hypothalamus to regulate feeding behavior [124, 125]. Leptin 
receptors (ObR) exist as six different isoforms (ObRa–ObRf), 
classified as short (ObRa, ObRc, OBRd, and ObRf), long (ObRb), and 
secreted (ObRe) isoforms [126]. All isoforms, except ObRe, are 
transmembrane receptors that share the characteristic of possessing a 
box 1 motif-binding Janus kinase (JAK)2 [127]. ObRb is considered 
the main functional receptor of leptin [128, 129]. By binding to ObRb, 
leptin activates multiple signaling cascades, such as JAK2–STAT3 
(signal transducer and activator of transcription) [130], mitogen 
activated protein kinase/extracellular signal-regulated kinase 
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(MAPK/ERK) [131], and phosphatidylinositol 3-kinase/protein kinase 
B (PI3K/Akt) pathways [132]. The major anti-obesity effects of leptin 
are initiated by the phosphorylation of JAK2. The activation of JAK2 
permits STAT3 phosphorylation and nuclear translocation. Nuclear 
phospho-STAT3 acts as a transcription factor for STAT3-targeted 
genes [133, 134]. 
The energy balance system involves long-term afferent signals from 
fat (leptin) and pancreatic β cells (insulin). Leptin regulates glucose, 
lipid and energy homeostasis as well as feeding behavior, serving as a 
bridge between peripheral metabolically active tissues and the CNS, 
promoting fat mass loss and body weight reduction. Indeed, this 
hormone, whose circulating levels mirror fat mass, not only exerts its 
anti-obesity effects mainly modulating the activity of specific 
hypothalamic neurons expressing the long form of the leptin receptor 
(Ob-Rb), but it also shows pleiotropic functions due to the activation 
of Ob-Rb in peripheral tissues [135]. This adipokine exerts metabolic 
effects in peripheral tissues directly and indirectly through the CNS 
[136, 137]. In fact, leptin modulates AMPK activity and 
orexigenic/anorexigenic neuropeptides in specific hypothalamic 
regions [136, 138, 139], leading to a reduction of appetite, and to an 
overall negative energy balance. However, obesity is often 
accompanied by leptin resistance. This latter phenomenon is defined 
as decreased sensitivity to the anorexigenic or weight loss effects of 
leptin accompanied by hyperleptinemia [77]. Nevertheless, several 
mechanisms have been suggested to mediate leptin resistance, 
including obesity-associated hyperleptinemia, impairment of leptin 
access to CNS and the reduction in Ob-Rb signal transduction 
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effectiveness. During the onset and progression of obesity, the 
dampening of leptin sensitivity often occurs, preventing the efficacy of 
leptin replacement therapy from overcoming obesity and/or its co-
morbidities [135]. Identifying the mechanisms by which leptin 
resistance develops is critical. Impairment of leptin signaling is 
thought to be one mechanism: suppressor of cytokine signaling 
(SOCS)3, a mediator of negative feedback to STAT3, is known to 
attenuate leptin-induced signaling, hence SOCS3-deficient mice 
displayed increased leptin-induced STAT3 phosphorylation in the 
hypothalamus [140]. Similarly, protein tyrosine phosphatase (PTP)1B 
dephosphorylates JAK2, thereby inhibiting leptin activity. Consistent 
with this action, deactivation of PTP1B results in a decrease in body 
weight and adiposity, and an increase in energy expenditure in mice 
[141]. Thus, SOCS3 and PTP1B are molecular mediators of leptin 
resistance, and involves the phosphorylation of STAT3, which is 
associated to the modulation of orexigenic/anorexigenic neuropeptides 
in the hypothalamus [77]. PTP1B inhibits leptin activities via 
dephosphorylation of JAK2 [142]. In fact, PTP1B knockout mice have 
increased sensitivity to leptin and are resistant to a HFD [143]. 
Therefore, development of potent and specific inhibitors of PTP1B has 
become interesting for the treatment of T2DM and obesity [144]. Over 
the last decades, several PTP1B inhibitors have been developed [145, 
146]. SOCS3 inhibits leptin-induced signal transduction [147]. 
Deletion of SOCS3 in hypothalamic neurons enhances leptin 
sensitivity, reduces appetite, and protects from HFD [148]; while 
overexpression of SOCS3 in proopiomelanocortin (POMC) neurons 
leads to hyperphagia and obesity [149]. Leptin receptor expressed in 
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the CNS mediate the anorexigenic effects of this hormone [150, 151]. 
Leptin suppress the activity of the orexigenic neuropeptide Y 
(NPY)/agouti-related protein (AgRP) neurons, while it stimulates the 
anorexigenic POMC/cocaine- and amphetamine-related transcript 
(CART) neurons [104, 152]. Therefore, the restoration of leptin 
sensitivity at hypothalamic level is consistent with the increase in 
POMC and the reduction of AgRP [77]. 
 
2.1.1. Glucose metabolism and insulin signaling pathways 
Many findings show the association among obesity, insulin-resistance 
(IR) and T2DM. IR is defined as inefficient glucose uptake and 
utilization in peripheral tissues in response to insulin stimulation. IR in 
the prediabetes stage is a feature of glucose intolerance, which 
includes impaired fasting glucose and/or impaired glycemic after bolus 
of glucose [153]. 
Insulin is a 51-residue anabolic peptide hormone secreted by the β-
cells of the pancreas that plays a critical role in the regulation of 
human metabolism. Containing two chains (A and B) connected by 
disulfide bonds, the mature hormone is the post-translational product 
of a single-chain precursor, designated proinsulin [154]. This hormone 
is widely known to reduce blood glucose levels via stimulation of 
glucose uptake by peripheral tissues, such as fat, liver, and skeletal 
muscle. Insulin also inhibits glucose production in liver, kidney and 
small intestine controlling blood glucose. Long-term exposure of 
tissues to elevated glucose concentrations is associated with the 
development of complications, including macro- and microvascular 
disease, and the typical retinopathy, nephropathy, neuropathy, 
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coronary heart disease, and cerebrovascular disease. Insulin signaling 
is triggered by the binding with its receptor and is mediated by protein 
kinase activity in the beta subunit of the insulin receptor (InsR) [155]. 
The InsR belongs to a superfamily of receptor tyrosine kinase whose 
activation modulates multiple post-receptor signaling pathways. This 
stimulation permits phosphorylation of the insulin receptor substrate 
(IRS) to promote the activation of the PI3K/Akt pathway, which is a 
major metabolic pathway of insulin [156]. In addition to its peripheral 
actions, insulin enters the brain from the circulation [157], and affects 
feeding behavior and energy homeostasis [158]. Insulin is synthesized 
by the  cells of the pancreas and is secreted rapidly after a meal, with 
a well characterized hypoglycemic effect [159]. However, insulin also 
acts as an anorectic signal within the CNS. 
Glucose is a carbohydrate, and is the most important simple sugar in 
human metabolism. Blood glucose is firstly transported into cells by 
the plasma membrane protein glucose transporter (GLUT). The GLUT 
family has been divided in several isoforms, GLUT-1, GLUT-2, 
GLUT-3 and GLUT-4. GLUT-1 is widely distributed in fetal tissues; 
GLUT-2 is expressed by renal tubular cells, liver cells and pancreatic 
 cells and it is also present in the basolateral membrane of the small 
intestine epithelium; GLUT-3 is expressed mostly in neurons and in 
the placenta; GLUT-4 is expressed in adipose tissues and striated 
muscle [160]. The insulin signaling pathway plays an important role in 
regulating its translocation (figure 7). 
When insulin binds to its transmembrane receptor, promotes its auto-
phosphorylation at tyrosine residues (pInsR). Activated pInsR recruits 
IRS and enhanced its activation by mediating its phosphorylation (p-
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IRS); p-IRS subsequently binds to the regulatory subunit, p85, of the 
PI3K and activates its catalytic subunit p110, which is responsible for 
stimulating the phosphoinositide-dependent kinase (PDK) [161] and 
its activation promotes the phosphorylation of Akt (pAkt) at Thr308 
and Ser473 residues [162]. 
 
 
Figure 7. Involvement of the insulin signaling pathway in the regulation of glucose transport. 
 
Phosphorylated Akt mediates the translocation of GLUT from the 
cytoplasm to the membrane mediating glucose uptake [163]. Akt has 
also been implicated in regulating glycogen synthesis. Glycogen 
synthase (GS) is a key enzyme involved in converting glucose into 
glycogen [164] as energetic reserve. 
 
2.1.2. Role of low grade inflammation 
Obesity is also characterized by chronic low grade inflammation. 
Systemic inflammation may play a crucial role in the pathogenesis of 
various obesity-related complications, including metabolic syndrome, 
T2DM, cardiac disease, liver dysfunction, and cancer. There is 
accumulating interest in the role of adipose tissue macrophages (ATM) 
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as inflammatory players in obesity [165]. ATMs, accumulated in 
adipose tissue, consist of at least two different phenotypes: classically 
activated M1 macrophages and alternatively activated M2 
macrophages [166]. ATM isolated from lean animals expressed 
hallmarks of polarization toward M2 macrophages with IL-10 and 
arginase expression, whereas in obese animals with IR a shift to M1-
polarized ATM with increased tumor necrosis factor (TNF)-α and IL-6 
[167]. These cytokines can block insulin action via autocrine/paracrine 
signaling and cause systemic IR, providing a potential link between 
inflammation and IR [168, 169]. Therefore, in the blood of obese 
subjects, TNF-α and IL-6 are significantly increased. TNF-α binds to 
its receptor and induces iNOS production. ILs, IL-6 in particular, bind 
to corresponding receptors and promote the expression of SOCS3. All 
cytokines induce IRS1 protein degradation, which suppresses the 
PI3K/Akt signaling pathway, and subsequently suppresses GLUT 
translocation and glycogen synthesis, which results in IR and 
hyperglycemia (figure 8). 
 
 
Figure 8. Suppression of the PI3K/Akt signaling pathway mediated by insulin IRS1 
degradation. 
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2.1.3. Adenosine Monophosphate-Activated Protein Kinase and lipid 
homeostasis 
Adenosine Monophosphate-Activated Protein Kinase (AMPK) is a 
sensor and regulator of cellular energy metabolism, including obesity 
[170]. AMPK is a serine/threonine protein kinase which 
physiologically responds to the change in the cellular AMP to ATP 
ratio. AMPK is composed of 3 subunits (α, β, and γ): a catalytic 
subunit (α1 or α2) and two regulatory subunits (β1 or β2 and γ1, γ2 or 
γ3) [170] and its activation starts with phosphorylation of threonine-
172 in the catalytic domain of the α subunit [171]. AMPK activation 
regulates physiological and pathological responses in different tissues. 
AMPK activation induces fatty acid oxidation not only in liver and 
heart, but also in skeletal muscle [172] inhibits hepatic lipogenesis and 
adipocyte differentiation, and stimulates glucose uptake in muscle. 
Increasing fatty acid utilization appears to be an attractive way to 
prevent both obesity and IR, which are characterized by intra-muscular 
and hepatic lipid accumulation [173]. In the liver, AMPK enhances 
fatty acid oxidation by phosphorylating acetyl-CoA-carboxylase 
(ACC), one of the main enzymes for the synthesis of malonyl-CoA, 
which is the substrate for fatty acid synthesis and a potent allosteric 
inhibitor of CPT [174, 175]. Under normal conditions, the inhibition 
of ACC through phosphorylation, leads to a decrease of malonyl-CoA 
levels, permitting to CPT-1 to transport fatty acids into mitochondria 
and fatty acid utilization. This event leads to fat burning in liver and 
muscle. AMPK also represses pyruvate kinase and fatty acid synthase 
expression, thus contributing to decreased lipogenesis [176]. 
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AMPK can stimulate hepatic PPAR- activity, as a sensor of the 
intracellular energy state activated by high AMP-to-ATP ratios, i.e., 
during fasting [177]. Indeed, PPAR- also controls, directly or 
indirectly, lipogenic pathways in the liver, besides its ability to 
orchestrate lipoprotein metabolism [178]. As shown in figure 9, 
lipogenesis is the metabolic pathway allowing fatty acid synthesis 
when dietary carbohydrates or fats are abundant. 
 
 
Figure 9. Molecular switch of PPAR-α activity in the fed-to-fasted state. 
34 
 
 
2.2. Non-alcoholic fatty liver disease (NAFLD) 
The liver is the second largest organ in the body. It performs many 
activities: it processes what we eat and drink into energy and nutrients 
the body can use. The liver also removes harmful substances from 
blood. This important organ is subjected to several pathologies. Non-
alcoholic fatty liver disease (NAFLD), or steatosis, is one of the most 
common co-morbidities associated with overweight, metabolic 
disorders and IR. The liver produces and is exposed to various types of 
lipids, such as fatty acids, cholesterol and triglycerides via the portal 
vein from the diet and visceral adipose tissues. The liver and adipose 
tissue jointly participate in maintaining glucose and lipid homeostasis 
through the secretion of several humoral factors and/or neural 
networks [179]. NAFLD is one of the most dangerous complications 
because it can lead to severe liver pathologies, including fibrosis, 
cirrhosis and hepatic cellular carcinoma (HCC). 
A recent meta-analysis raised the question whether NAFLD is a 
prodromic event of MetS rather than just its hepatic manifestation 
[180]. Evidence indicate that the effects of NAFLD extend beyond the 
liver and are negatively associated with a range of chronic diseases, 
most notably CVD, T2DM and chronic kidney disease. A small group 
of people with NAFLD may progress in a more serious condition, non-
alcoholic steatohepatitis (NASH), where fat accumulation is associated 
with liver cell inflammation. NASH is a potentially serious condition 
that may lead to severe liver scarring and cirrhosis. Cirrhosis occurs 
when the liver sustains substantial damage, and the hepatic cells are 
gradually replaced by scar tissue, which results in the inability of the 
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liver to work properly [181]. NASH is common in patients with 
obesity, IR and T2DM and NASH increases the risk of HCC [182] 
(figure 10). The mechanisms that promote HCC development in 
patients with NAFLD or NASH is poorly understood. Several 
molecular mechanisms have been linked to obesity and its related 
metabolic diseases, accelerating cancer process. Among these adipose-
derived inflammation, lipotoxicity and IR play a pivotal role, as well 
as mitochondria dysfunction [183]. 
 
 
Figure 10. Sequential steps of NAFLD pathology. NAFLD develops following a sequence 
of events from steatosis to NASH, which can progress to additional liver damage. 
Representative pictures are shown (left to right) of a normal liver, steatosis displaying lipid-
filled hepatocytes. 
 
NAFLD is an example of fat accumulation and this lipid accumulation 
is usually associated with increased secretion of hepatokines [184] 
increased gluconeogenesis, decreased glycogen synthesis and 
inhibition of insulin signaling [185]. Activation of certain metabolic or 
stress-response pathways, involving NF-кB, phosphatase and tensin 
homolog (PTEN), occurs in HCC [186]. Many of these pathways 
involved in causing cellular stress also occur within tissues affected by 
obesity, IR [187] which are commonly linked and important in the 
pathogenesis of T2DM. It has also been suggested that chronic 
activation of toll-like receptor (TLR)-4, an upstream activator of NF-
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кB signaling [188], by gut microbiota-derived ligands such as 
lipopolysaccharide, may occur. The possibility that alterations in the 
gut microbiota promote the development of T2DM and NAFLD, 
makes the gut microbiota an attractive and potentially new therapeutic 
target in NAFLD (and possibly in T2DM as well, where there is 
obesity and IR). 
Although obesity is strongly associated with hepatic steatosis, excess 
body fat accumulation is not an essential condition for developing 
NAFLD. In fact, patients with lipodystrophy have marked IR and 
commonly develop hepatic steatosis and T2DM, strongly suggesting 
that adipose tissue dysfunction is the key contributor to the 
pathogenesis of NAFLD [189]. Specifically, increased free fatty acid 
(FFA) fluxes from the adipose tissue pool increase the availability of 
long-chain fatty acyl-CoAs for hepatic lipid accumulation, particularly 
in physically inactive individuals, and evidence is accumulating that 
hepatic lipid accumulation is capable of causing hepatic/peripheral IR 
and promotes hepatic inflammation [190]. 
 
2.3. Hypertension 
Hypertension in MetS differs from other forms of hypertension and 
recent studies have underlined these differences in many ways [191]. 
Higher cardiometabolic risk profile is characterized by a close 
relationship between high serum triglycerides and elevated waist 
circumference, as displayed by risk ratio for future coronary artery 
disease of 2.40 in men and of 3.84 in women [192]. 
Excess visceral fat is not only related in the risk for coronary heart 
disease, but it is also associated with hypertension [193]. Among all 
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factors influencing systolic and diastolic blood pressure, the waist 
circumference in men and women has showed to be the strongest one 
[194]. It is known that the pathophysiological link between visceral fat 
and cardiovascular diseases is multifactorial. One mechanism might be 
the association of visceral and ectopic fat accumulation, e.g. fatty 
degeneration of cardiac cells. It has been shown that visceral obesity is 
the best predictor for epicardial and pericardial fat [195]. Moreover, 
weight loss associated with a decrease of visceral fat in severely obese 
subjects significantly reduces epicardial fat thickness [196]. 
Pericardial fat correlates with adiposity, vascular calcification, and 
further cardiovascular risk factors [197]. An increase of CVD risk, is 
due to an accumulation of visceral adiposity in contrast to 
subcutaneous fat, facilitating arteriosclerosis, hypertension, and fat 
accumulation of the heart. 
In hypertensive and obese subjects there is an endothelial dysfunction, 
characterized by an increased synthesis of angiotensin (Ang) II, the 
main vasoconstrictor protein, that results from Ang I in a reaction 
catalyzed by the angiotensin converting enzyme (ACE). 
The endothelium plays an important role in maintaining vascular 
homeostasis by synthesizing and releasing several vasoactive 
substances [198]. 
In vasodilating pathway, prostacyclin, NO and a family of 
endothelium-derived hyperpolarizing factors (EDHFs) are the main 
actors. Endothelium-derived NO mediates vascular relaxation of 
relatively large, conduit arteries, while EDHF plays an important role 
in modulating vascular tone in small resistance arteries in rodents 
[199, 200] and in human forearm microcirculation [201, 202]. 
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The alteration of normal endothelial function, therefore, is the cause of 
many CVDs, such as hypertension, coronary artery disease, 
myocardial infarction and vascular complications. 
 
2.3.1. Arachidonate metabolites and cardiovascular function 
It is well known that cyclooxygenase (COX) and lipoxygenase 
metabolize AA in 5, 12 and 15- hydroxyeicosatetraenoic acids 
(HETE), prostaglandins, prostacyclin, leukotrienes and thromboxane. 
These products modulate the renal and pulmonary functions, vascular 
tone and inflammatory response [203]. 
However, many years ago, it was discovered a third pathway of AA 
metabolism: it was reported that AA is also metabolized by the 
enzymatic pathway of CYP450, including epoxygenase and 
hydroxylase enzymes, in the liver and kidney to epoxyeicosatrienoic 
acids (EET) and HETE (figure 11) [204, 205]. Discovery of the ability 
of CYP to transform AA into products that possess a myriad of potent 
biological activities has uncovered novel arachidonate metabolites that 
function as key components in mechanisms that participate in 
circulatory control and the regulation of renal function [206, 207]. 20-
HETE, the principal CYP product of renal and cerebral arterioles, 
mediates the regulation of these vasculatures [208, 209]; 20-HETE 
also modulates electrolytic transport in key nephron segments [210]; 
20-HETE and a labile epoxide, 5,6-EET, are second messengers, 
accounting for many of the several actions of peptide hormones as 
mitogens, secretagogues, vasoactive agents, and regulators of volume 
and composition of body fluids [206, 207]. 
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Figure 11. The metabolites of AA from three independent enzymes. Four regioisomeric cis-
EETs are primary products of AA metabolism by CYP450 epoxygenases. HETEs are primary 
products of AA metabolism by CYP450 hydroxylase. COX, cyclooxygenase; LOX, 
lipoxygenase; EET, epoxyeicosatrienoic acid; HETE, hydroxyeicosatetraenoic acids. 
 
EETs are CYP epoxygenase metabolites of AA, produced by the 
vascular endothelium in response to agonists, such as bradykinin and 
acetylcholine (Ach), or physical stimulus, such as shear stress [211]. 
EETs are hydrolyzed by soluble epoxide hydrolase (sEH) in the 
corresponding inactive diols, dihydroxyeicosatrienoic acids (DHETs), 
resulting in attenuation of the vasodilation and anti-inflammatory 
effect of EETs. EET hydrolysis has been found to be increased in renal 
fractions of SHR, an animal model of Ang II-mediated hypertension 
[212]. Consistently, sEH was found increased in SHR renal 
microsomes and cytosol [212] and in renal micro-vessels of Ang II-
induced hypertensive rats [213]. sEH expression has been shown to be 
also increased in aortas from saline-fed SHR or Ang II-treated 
normotensive rats. The transcriptional regulation of sEH expression by 
Ang II has been demonstrated to be mediated by angiotensin II type 
(AT)1 receptor, since a selective AT1 antagonist reversed this effect 
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[214]. Therefore, the increased expression of sEH has been interpreted 
as a result of AT1 and downstream signaling cascade activation, 
leading to activator protein (AP)-1 transcriptional activity. The 
enhanced hydrolysis of EETs in DHETs by sEH would unbalance 
vascular tone and hence increase systemic blood pressure. The 
administration of an inhibitor of sEH increases the renal formation of 
EETs and reduces the pressure in the SHR. Further evidence of a 
function for the sEH and the EET in the blood pressure’s control has 
been reported [215]. Furthermore, it was found that sEH gene deletion 
increases the renal formation of EET and the reduction in blood 
pressure of 13 mmHg in male mice [215]. 
EET, DHETs and 20- HETE act mainly as autocrine factors. These 
compounds are very lipophilic and, in high concentrations was found 
in tissues rather than, in plasma, urine or interstitial fluid. Moreover, 
EETs and 20-HETE bind to protein and albumin [216], limiting their 
distribution in the vascular space when administered systemically. 
Molecular and cellular mechanisms, by which EETs regulate different 
biological functions, have been widely observed. The most frequent 
perplexity, concerns the possibility of EETs to exert different 
biological effects. 
Campbell et al. [217] reported the effect of EET on the relaxation of 
smooth muscle cells and coronary arteries, through hyperpolarization 
induction mediated by the activation of calcium-activated potassium 
channels (KCa
2+), identifying the EET as EDHF. 
Following studies showed that hyperpolarizing effects play a role also 
in peripheral arteries [218] as well as, and in airway smooth muscle 
cells [219]. Indeed, Lu et al. [220] and Ke et al. [221] showed that 
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EETs had a protective effect at cardiac level, activating the ATP-
dependent potassium channels in cardiac sarcolemma, leading 
myocardial cells hyperpolarization. 
 
2.3.2. Renin-angiotensin system (RAS) 
Renin-angiotensin system (RAS) is a major long-term regulator of 
important physiological processes including the regulation of the 
pressure of the homeostasis of fluids and electrolytes [222]. In fact, 
pharmacological impairment of RAS has shown that this system can 
contribute to major cardiovascular diseases. However, recently it has 
been shown that this system can also play a role in the development of 
other pathological conditions, such as atherosclerosis, myocardial 
infarction, heart failure and T2DM [223, 224]. Renin converts an 
inactive peptide, angiotensinogen, in Ang I, that it is converted in Ang 
II by ACE, mainly expressed at pulmonary capillary level. Ang II is 
the major bioactive product of RAS and exerts both endocrine and 
autocrine/paracrine hormonal actions. The circulating Ang II induces 
vasoconstriction and promotes the release of aldosterone from the 
adrenal gland. The Ang II may be further split to form Ang III and 
Ang IV. Actions of RAS include not only endocrine functions but also 
a paracrine activity in districts, such as brain, heart, vascular tissue, 
that contain components of the RAS and thus are able locally to 
generate Ang II [225]. The Ang II acts through the activation of two 
transmembrane receptor subtypes G-protein coupled, AT1 and AT2. 
Most of actions of Ang II, including blood pressure, fluid and 
electrolyte regulation, appear mediated by the activation of AT1. It is 
important to underline that AT1 activation leads to an inflammatory 
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response by the vascular wall. Two mechanisms are involved in Ang 
II-induced inflammatory response: generation of reactive oxygen 
species (ROS) and activation of the NF-кB in vascular tissue [226]. 
There is evidence for RAS over-activation in obesity; indeed, RAS 
blockade induced IR, indicating its involvement in the pathogenesis of 
IR in obesity [227]. Pharmacologically, the strongest clinical evidence 
for an association between systemic RAS and IR originates from 
clinical trials which have shown that RAS blockade reduces the risk 
for developing T2DM [228, 229]. Pharmacological RAS blockade also 
improves insulin sensitivity in several rodent models of obesity or IR 
[230, 231]. 
 
2.4. Metabolic syndrome (MetS) 
As mentioned before obesity can be defined as an excess of body fat, 
accompanied by other several complications defined as MetS.  
In particular, the National Cholesterol Education Program’s Adult 
Treatment Panel III report (ATP III) [232] identified the MetS as a 
multiplex risk factor for CVD that is deserving of more clinical 
attention. ATP III identified 6 components of the metabolic syndrome 
that relate to CVD (figure 12): 
 abdominal obesity 
 atherogenic dyslipidemia  
 raised blood pressure  
 IR ± glucose intolerance 
 pro-inflammatory state  
 pro-thrombotic state  
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The advantage of measuring waist circumference is that an excess 
abdominal fat is correlated more closely with the presence of 
metabolic risk factors than total body fat. Adiposity is associated with 
a state of low-grade chronic inflammation, with increased TNF-α and 
IL-6 release, which interfere with adipose cell differentiation, and the 
action pattern of adiponectin and leptin until the adipose tissue begins 
to be dysfunctional. In this state, the subject presents IR and 
hyperinsulinemia, probably the first step of a dysfunctional metabolic 
system. In subjects with MetS an energy balance is critical to maintain 
a healthy body weight, mainly limiting the intake of high energy 
density foods (fat). The first factor to be avoided in the prevention of 
MetS is obesity, and the percentage of fat in the diet has traditionally 
been associated with the development of obesity [233]. 
 
            
Figure 12. Pathogenesis of elevated cardiovascular risk in the MetS. 
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EXPERIMENTAL SECTION 
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Materials and Methods 
3. Model of genetic spontaneously hypertensive rat 
(SHR) 
 
3.1. Animals and treatments 
Eight-week-old male SHRs and age-matched Wistar Kyoto 
normotensive (WKY) rats, obtained from Harlan Italy, were used for 
this study. Animals were housed in temperature (23±2°C) and light-
controlled (12:12-hours light-dark cycle) condition and food and water 
freely available. The animals were divided into four groups (n = 10): 
(1) WKY and (2) SHR control; (3) WKY and (4) SHR rats receiving 
PEA (30 mg/kg/die subcutaneous injection). 
PEA (Tocris Cookson Ltd., UK) was dissolved in PEG400 and Tween 
80 2:1 (Sigma-Aldrich, Milan, Italy). Control WKY and SHR received 
PEA vehicle. All animals were treated for 35 days (five weeks). The 
experimental design is described in figure 13: 
 
                    
         Figure 13. Experimental protocol of genetic spontaneously hypertensive rats. 
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Throughout the experimental period, systolic blood pressure (SBP) 
was monitored in conscious rats. At the end of the treatment period, 
animals were anesthetized, to minimize pain, and euthanized for blood 
and tissue collection. 
 
3.2. Serum determinations 
14,15-DHET was measured by using an enzyme-linked 
immunosorbent assay (14,15-DHET ELISA kit; Detroit R&D Inc., 
Detroit, MI, USA). Glucose levels were measured by the glucometer 
One Touch Ultrasmart (Lifescan, Milpitas, CA). Insulin concentrations 
were measured by rat/mouse insulin ELISA kit (cat. no. EZRMI-13K; 
Millipore). As index of IR, HOMA-IR (HOmeostasis Model 
Assessment) was calculated, using the formula [HOMA=fasting 
glucose (mmol·l-1) x fasting insulin (μU·ml-1)/22.5]. 
 
3.3. Measurement of arterial blood pressure in conscious rats 
SBP was measured in conscious rats with a non-invasive common 
indirect method using a tail-cuff device in combination with blood 
flow sensor and recorder (Ugo Basile, Biological Research 
Apparatus). Briefly, rats were housed for 30 minutes in a warmed 
room (28–30°C), then a tail cuff was placed about 2 cm from the base 
of the tail for measuring systolic blood pressure. Care was taken in 
selecting an appropriate cuff size for each animal. Rats were allowed 
to habituate to this procedure for 2 weeks before the start of treatment. 
SBP was measured between 09:00 and 12:00 a.m. and values were 
recorded and were averaged from at least three consecutive readings 
per rat. 
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3.4. Isolated and perfused mesenteric bed 
These experiments were conducted in collaboration with prof. 
Sorrentino and prof. d’Emmanuele di Villa Bianca. In brief, rats were 
euthanized and the superior mesenteric artery was cannulated to 
perfuse the whole vascular bed with Krebs’ buffer containing heparin 
(10 IU/ml; Sigma-Aldrich, Milan, Italy) for 5 minutes at 2 ml/min. 
Mesenteric bed was separated from the intestine by cutting along the 
closed intestinal border and connected to a pressure transducer 
(Bentley 800 Trantec; Ugo Basile, Comerio, Italy). 
It was perfused with Krebs’ buffer (2 ml/min) composed of 115.3 mM 
NaCl, 4.9 mM KCl, 1.46 mM CaCl2, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 25.0 mM NaHCO3, and 11.1 mM glucose (Carlo Erba 
Reagents, Milan, Italy), warmed at 37°C, and oxygenated (95% O2, 
5% CO2). After approximately 20 minutes of equilibration, 
methoxamine (MTX, 100 μM; Sigma-Aldrich), an adrenergic α1-
agonist was added to the Krebs’ solution. In order, to visualize NO 
synthase (NOS) and COX-independent relaxation i.e., EDHF, a 
concentration-response curve of acetylcholine (Ach bolus injection; 1-
10-100-1000 pmoles; Sigma-Aldrich; Milan, Italy) was performed on 
stable tone of MTX in Krebs’ solution medicated with indomethacin 
(INDO; 10μM; Sigma-Aldrich) and NG-nitro-L-arginine methyl ester 
(L-NAME, 100μM; Sigma-Aldrich) as COX and NOS inhibitors, 
respectively. 
 
3.5. Western blot analysis 
Mesenteric tissues and carotids were excised, harvested, frozen in 
liquid nitrogen and stored for protein evaluations. Later tissues were 
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homogenized on ice in lysis buffer (Tris-HCl, 20 mM pH 7.5, 10 mM 
NaF, 150 mM NaCl, 1% Nonidet P-40, 1 mM phenylmethylsulphonyl 
fluoride, 1 mM Na3VO4, 10 μg/ml leupeptin and trypsin inhibitor). 
After 1 h, tissue lysates were obtained by centrifugation at 13000 rpm 
for 20 minutes at 4°C. The protein concentration of the samples was 
determined by Bio-Rad protein assay (Bio-Rad Laboratories, Segrate, 
Milan, Italy), using bovine serum albumin as standard. For Western 
blot analysis, 35 μg protein of tissue lysate was dissolved in 
Laemmli’s sample buffer, boiled for 5 minutes, and subjected to SDS-
PAGE (8% or 12% polyacrylamide). The blot was performed by 
transferring proteins from a slab gel to nitrocellulose membrane at 240 
mA for 40 minutes at room temperature. The filter was then blocked 
with 1x PBS, 5% non-fat dried milk for 40 minutes at room 
temperature and probed with rabbit polyclonal antibodies anti-sEH or 
anti-AT1 or anti-ACE (1:2000; Upstate Biotechnology, Lake Placid, 
NY, USA) or anti-IκBα (1:200, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA), or phospho-signal transducer and activator of 
transcription (STAT)3 or STAT3 (1:1000; Cell Signaling Technology, 
Danvers, MA, USA) or phospho-extracellular signal-regulated-kinases 
(ERK) 1/2 (1:200; Cell Signaling Technology, Danvers, MA, USA) 
dissolved in 1x PBS, 5% non-fat dried milk, 0.1% Tween 20 at room 
temperature, overnight or for 2 hours. The secondary antibody (anti-
rabbit IgG-horseradish peroxidase conjugate 1:5000 dilution) was 
incubated for 1 hour at room temperature. Subsequently, the blot was 
extensively washed with PBS, developed using enhanced 
chemiluminescence detection reagents (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA) and the immune complex visualized by Image 
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Quant. The protein bands were scanned and densitometrically 
analyzed with a model GS-700 imaging densitometer (Bio-Rad 
Laboratories, Milan, Italy). Western blot for α-tubulin (Sigma; St. 
Louis, MO, USA) was performed to ensure equal sample loading. 
 
3.6. Statistical analysis 
Data are presented as mean ± SEM. Statistical analysis was performed 
by ANOVA test for multiple comparisons followed by Bonferroni’s 
test, using Graph-Pad Prism (Graph-Pad software Inc., San Diego, 
CA). Statistical significance was set at P<0.05. 
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4. Mouse model of diet-induced obesity (DIO) 
 
4.1. Animals and treatments 
Male C57BL/6J mice (Harlan, Italy) at 6 weeks of ages, were housed 
in stainless steel cages in a room kept at 22±1°C with a 12:12 hours 
lights-dark cycle. All procedures involving the animals were carried 
out in accordance with the Institutional Guidelines and complied with 
the Italian D.L. no.116 of January 27, 1992 of Ministero della Salute 
and associated guidelines in the European Communities Council 
Directive of November24, 1986 (86/609/ECC). All animal procedures 
reported herein were approved by the Institutional Animal Care and 
Use Committee (CSV) of University of Naples “Federico II” under 
protocol no. 2011–0129170. Standard chow diet had 17% fat, without 
sucrose while HFD for diet-induced obesity (DIO), had 45% of energy 
derived from fat, 7% of sucrose. Standard and HFD contained 3.3 
kcal/g and 5.24 kcal/g, respectively. After weaning, young mice were 
randomly divided into four groups (at least 10 animals for each group) 
as follows: 1) control group (STD) receiving chow diet and vehicle by 
gavage (per os); 2) STD group treated with PEA (STD+PEA, 30 
mg/kg/die per os); 3) DIO group receiving vehicle; 4) DIO group 
treated with PEA (DIO+PEA, 30 mg/kg/die per os). The PEA 
treatments started after 12 weeks of feeding with STD or HFD and 
continued for 10 weeks. Ultramicronized PEA was provided by 
Epitech Group Research Labs and was suspended in carboxymethyl 
cellulose (1.5%, 300 μl per mouse). In figure 14 the scheme of 
experimental protocol and animal treatments are shown. 
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Figure 14. Experimental protocol of DIO model. 
 
4.2. Body weight, food intake, blood pressure and body gain in fat 
During the experimental period, body weight was assessed one time 
each week, while food intake was evaluated every day. Lastly, food 
intakes were cumulated. The systolic blood pressure (SBP) was 
recorded in conscious mice by a tail cuff connected to a blood pressure 
recorder (Blood Pressure Recorder, Ugo Basile Apparatus, Comerio, 
Italy). After a week of training period, mice were treated as described 
above and blood pressure was monitored every 2 days. At the end of 
the experimental protocol, before sacrifice, bioelectrical impedance 
analysis was applied to determine fat body composition assessment 
using BIA 101 analyzer, modified for the mouse (Akern, Florence, 
Italy). Fat free mass was calculated and fat mass content was 
determined as the difference between body weight and fat-free mass. 
Fasting glucose levels were measured by the glucometer One Touch 
Ultrasmart (Lifescan, Milpitas, CA).  
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4.3. Glucose and insulin tolerance tests 
Glucose tolerance test (OGTT) was performed in 12 hours fasted 
animals, which received oral glucose (1g/kg) and glycaemia was 
measured at 0, 30, 60, 90 and 120 minutes. 
Insulin tolerance test (ITT) was performed in 5 hours fasted mice. 
After determination of basal blood glucose levels, each animal 
received an intraperitoneal injection of insulin (Humulin, Lilly), 0.75 
U/kg. Blood glucose levels were measured at 15, 30, 60, 90 and 120 
minutes after insulin injection. The areas under the curve (AUC) were 
calculated from time zero, as integrated and cumulative measure of 
glycaemia up to 120 minutes for all animals. Glucose levels were 
measured by the glucometer One Touch Ultrasmart (Lifescan, 
Milpitas, CA). 
 
4.4. Pyruvate tolerance test (PTT) 
One week before sacrifice, in overnight fasted mice pyruvate tolerance 
test (PTT) was carried out. After the serum glucose determination, 
fasted animals were injected intraperitoneally with pyruvate (Sigma), 
2g/kg and glycaemia was measured at 15, 30, 60 and 120 minutes after 
pyruvate. The areas under the curve (AUC) was calculated from time 
zero, as integrated and cumulative measure of glycaemia up to 120 
minutes for all animals. Glucose levels were measured by the 
glucometer One Touch Ultrasmart (Lifescan, Milpitas, CA). 
 
4.5. Tissue collection, hematic parameters and triglycerides content 
STD and DIO mice, treated or not with PEA for 10 weeks, were 
sacrificed after overnight fasting. Blood collected by cardiac puncture 
was centrifuged at 2500 rpm at 4°C for 12 minutes, and sera were 
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stored at -80°C for later biochemical and hormonal determinations. 
Alanine amino transferase (ALT), aspartate amino transferase (AST), 
total cholesterol, low density lipoprotein (LDL) and triglycerides 
(TGL), leptin, adiponectin, TNF-α, monocyte chemoattractant protein 
(MCP)-1 and IL-1 were measured by ELISA kits. Fasting insulin 
concentrations were measured by rat/mouse insulin ELISA kit (cat. no. 
EZRMI-13K; Millipore). As index of IR, HOMA-IR (HOmeostasis 
Model Assessment) was calculated, using the formula 
[HOMA=fasting glucose (mmol l-1) x fasting insulin (μU ml-1)/22.5]. 
About 200 mg of liver sample were added with 2 ml of a solution 
(0.9% NaCl) and sonicated. The mixture was vortexed for 20 s. Then, 
was centrifuged at 5.000 rpm for 5 minutes to room temperature. The 
supernatants were collected and was again centrifuge. The 
supernatants were collected and stored at −80°C for following liver 
triglycerides determination. 
 
4.6. Western blotting 
Liver was homogenized and total protein lysates were obtained using 
complete lysis buffer containing 20 mM Tris–HCl (pH 7.5), 10 mM 
NaF, 150 mM NaCl, 1% Nonidet P-40, 1 mM phenylmethylsulphonyl 
fluoride (PMSF), 1 mM sodium orthovanadate (Na3VO4), leupeptin 
and trypsin inhibitor (10 μg/ml). After 1 hour, cell lysates were 
obtained by centrifugation at 13.000×g for 15 minutes at 4°C. 
Protein concentrations were determined by the Bio-Rad protein assay 
using bovine serum albumin as standard. Equal amount of protein was 
subjected to 10% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membrane. The blot 
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was performed by transferring proteins from a slab gel to 
nitrocellulose membrane at 240 mA for 60 minutes at room 
temperature. The filter was then blocked with 1X PBS and 5% nonfat 
dried milk for 60 minutes at room temperature and probed with rabbit 
polyclonal antibody against anti GLUT-2 (dilution 1:1000, Millipore 
Corporation, Billerica, MA, USA), or anti phospho Akt (pAkt, dilution 
1:1500; Cell Signaling Technology, Danvers, MA, USA) or anti Akt 
(dilution 1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or 
phosphor InsR (pInsR, dilution 1:250; Thermo Scientific, Rockford, 
USA) or InsR (dilution 1:1000; Cell Signaling Technology, Danvers, 
MA, USA.), or phosphor AMPK (pAMPK, dilution 1:250, Cell 
Signaling Technology, Danvers, MA, USA) or AMPK (dilution 1:500, 
Cell Signaling Technology, Danvers, MA, USA), phospho ACC 
(pACC, dilution 1:1000, Cell Signaling Technology, Danvers, MA, 
USA) or ACC (dilution 1:1000, Cell Signaling Technology, Danvers, 
MA, USA), or PPAR-α (dilution 1:100, Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA). Western blot for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; Sigma-Aldrich, Milan, Italy) was performed 
to ensure equal sample loading. 
 
4.7. Real-time semi-quantitative PCR 
Total RNA, isolated from liver was extracted using TRIzol Reagent 
(Bio-Rad Laboratories), according to the manufacturer’s instructions. 
cDNA was synthesized using a reverse transcription kit (Nucleospin®, 
MACHEREY-NAGEL GmbH & Co, Düren, Germany) from 6 μg 
total RNA. PCRs were performed with a Bio-Rad CFX96 Connect 
Real-time PCR System instrument and software (Bio-Rad 
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Laboratories). The PCR conditions were 15 minutes at 95°C followed 
by 40 cycles of two-step PCR denaturation at 94°C for 15 s, annealing 
extension at 55°C for 30 s and extension at 72°C for 30 s. Each sample 
contained 500 ng cDNA in 2X QuantiTech SYBRGreen PCR Master 
Mix and primers, TNF-α and IL-6 (Qiagen, Hilden, Germany). The 
relative amount of each studied mRNA was normalized to GAPDH as 
housekeeping gene, and the data were analyzed according to the 2-ΔΔCT 
method. 
 
4.8. c-fos staining 
Overnight fasted male mice were injected (i.p.) with vehicle or PEA 
(30 mg/kg) at 09:00 a.m. Mice were anaesthetized by isofluorane and 
killed by perfusion fixation (4% paraformaldehyde in 0.1 M phosphate 
buffer saline), followed by overnight post-fixation in 4% 
paraformaldehyde. After 30 minutes washing in phosphate buffer, 
brains were cut into 50 μm tick sections and the same that containing 
the ARC were collected. After 15 minutes in buffer, the sections were 
incubated in blocking solution for 30 minutes at room temperature. 
The primary antibody goat anti c-fos (Santa Cruz Biotechnology) was 
then applied overnight at room temperature. The next day, sections 
were washed 3 times in buffer and incubated with the secondary 
antibody for 1 hour at room temperature. Finally, the sections were 
analyzed using fluorescence microscopy. 
 
4.9. Statistical analysis 
All data were presented as mean ± SEM. Statistical analysis was 
performed by ANOVA test followed by Bonferroni’s test for multiple 
comparisons. Statistical significance was set at P<0.05. 
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5. In vitro cell models 
5.1. Induction of IR in human neuroblastoma cell line 
 
5.1.1. Cell culture 
SH-SY5Y human neuroblastoma cells were grown in DMEM 
(Dulbecco’s modiﬁed Eagle’s medium)-F12 and EMEM (Eagle’s 
modiﬁed essential medium) 1:1 supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin and 100 µg/ml streptomycin in 5% CO2 
atmosphere at 37°C. The medium was replaced every two days.  
 
5.1.2. Cell treatments and immunoblotting 
SH-SY5Y cells were starved in serum-free DMEM-F12 for 16 hours 
and stimulated with insulin (100 nM) in order to induce IR. To 
evaluate PEA effect, during insulin incubation, cells were treated with 
PEA (1 µM) the last 6 hours. Cells were then washed and re-
stimulated with the hormone for 10 minutes. After the stimulation, 
cells were washed twice with ice cold PBS, harvested, and re-
suspended in lysis buffer containing 20 mM Tris–HCl (pH 7.5), 10 
mM NaF, 150 mM NaCl, 1% Nonidet P-40, 1 mM 
phenylmethylsulphonyl fluoride (PMSF), 1 mM sodium orthovanadate 
(Na3VO4), leupeptin and trypsin inhibitor (10 μg/mL). After 1 hour, 
cell lysates were obtained by centrifugation at 13.000×g for 15 
minutes at 4°C. 
Protein concentrations were estimated by the Bio-Rad protein assay 
using bovine serum albumin as standard. Equal amount of protein was 
subjected to 10% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membrane. The blot 
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was performed by transferring proteins from a slab gel to 
nitrocellulose membrane at 240 mA for 60 minutes at room 
temperature. The filter was then blocked with 1X PBS and 5% nonfat 
dried milk for 60 minutes at room temperature and probed with rabbit 
polyclonal antibody against anti phosphor Akt (pAkt, dilution 1:1500; 
Cell Signaling Technology, Danvers, MA, USA) or anti Akt (dilution 
1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Western 
blot for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Sigma-
Aldrich, Milan, Italy) was performed to ensure equal sample loading. 
 
5.2. Induction of IR in human hepatocyte cell line 
 
5.2.1. Cell culture 
Human HepG2 cells (American Type Culture Collection, Manassas, 
VA, USA) were cultured in RPMI 1640 medium supplemented with 
10% FBS and 1% antibiotics (100 U/mL penicillin and streptomicin) 
at 37°C with 5% CO2. 
 
5.2.2. Cell treatments and immunoblotting 
HepG2 cells, starved in serum-free medium for 16 hours, were 
incubated with insulin (100 nM) or its vehicle for 24 hours to obtain 
insulin resistant and control cells, respectively [234]. To evaluate PEA 
effect, both control and insulin resistant cells were simultaneously 
treated with PEA (0.3, 1 and 3µM). After 24 hours, cells were washed 
and then challenged with 100 nM insulin for 10 minutes to determine 
insulin signaling pathway evaluating phospho Akt/Akt ratio. 
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5.3. In vitro statistical analysis 
All in vitro data are reported as mean ± standard error mean (S.E.M.) 
values of independent experiments, which were done at least three 
times, each time with three or more independent observations. 
Statistical analysis was performed by analysis of variance test, and 
multiple comparisons were made by Bonferroni’s test. 
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Results 
6. PEA prevents endothelial vascular dysfunction and 
hypertension, acting on EETs pathway and RAS in SHR 
 
6.1. Effect of PEA on IR and blood pressure 
Since hypertension, hyperglycemia and IR are important features of 
MetS, we evaluated fasting glucose and insulin levels in all rat groups 
(figure 15). 
 
Figure15. Effect of PEA on IR. PEA improve body glucose homeostasis. Fasting glucose 
(A), insulin levels (B) and HOMA-IR (C) were reported. Data are expressed as mean ± SEM 
(n=10 for each group). ***P< 0.001, **P<0.01 vs STD; ###P<0.001 and #P< 0.05 vs DIO. 
 
PEA did not modify all these metabolic parameters in control animals. 
Interestingly, the SHR receiving PEA, showed a decrease in glucose 
(figure 15A), a trend of reduction in insulin (figure 15B) and 
significant reduction of HOMA-IR (figure 15C) when compared to 
untreated SHR group. 
Moreover, SHR rats showed a significant increase in SBP (mmHg) 
values compared to WKY rats. No significant differences in blood 
pressure were observed in PEA-treated WKY rats compared to WKY, 
even if a trend of decrease was recorded. Conversely, a lowering effect 
on blood pressure was shown following PEA treatment of SHR for 5 
weeks compared to untreated SHR (figure 16A). In order to determine 
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the contribution of EDHF in mesenteric bed, as NOS- and COX-
independent relaxation, a concentration-response curve to Ach (1–
1000 pmoles) in Krebs solution medicated with INDO (10 μM) and L-
NAME (100 μM) was performed on MTX stable tone. The EDHF-
mediated relaxation resulted significantly reduced in SHR compared 
with WKY. Interestingly, the treatment with PEA caused a significant 
increase in EDHF-mediated relaxation in SHR compared with SHR 
untreated group. No significant effect was observed in WKY rats after 
PEA treatment (figure 16B). 
 
Figure 16. Effect of PEA on systolic blood pressure and EDHF-mediated relaxation on 
mesenteric arterial bed on stable tone of MTX Panel A shows systolic blood pressure 
(SBP) values of hypertensive (SHR) and normotensive (WKY) rats treated or not with PEA. 
Panel B shows EDHF contribution in the relaxation of mesenteric bed. ***P< 0.001, *P< 0.05 
vs WKY; ###P< 0.001, ##P<0.01 vs SHR. 
 
6.2. PEA reduces sEH expression in vascular tissues and increases 
serum levels of EETs 
To evaluate systemic EET hydrolysis, we analyzed sEH expression, by 
western blot analysis, of vascular tissues and DHETs concentration in 
serum of all animals. sEH is implicated in blood pressure control by 
virtue of its ability to degrade EETs that exert vasodilatory effects. 
Indeed, it is already known that sEH protein expression is increased in 
SHR, consistently with its hypertensive role. As shown in figure 17 
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immunoblots performed on mesenteric bed (figure 17A) and carotid 
(figure 17B) from SHR animals revealed a marked increase in sEH 
expression, which was significantly prevented by PEA treatment. 
Consistently, the increase in serum 14,15-DHETs shown in SHR, was 
significantly prevented by PEA (figure 17C), suggesting a reduced 
hydrolysis of EETs in PEA-treated SHR and hence an increase of their 
concentration. 
 
Figure 17. Effect of PEA on sEH protein expression in mesenteric bed and carotid. 
Immunoblot of sEH from mesenteric bed (A) and carotid (B) of SHR and WKY rats are 
shown. Serum 14-15DHET (ng/ml) is reported in panel C. Data are expressed as means ± 
SEM. ***P<0.001 and *P<0.05 vs WKY; ###P<0.001, ##P<0.01 and #P<0.05vs SHR. 
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6.3. PEA modulation of RAS in the vasculature 
 
6.3.1. PEA effect on AT1 and ACE expression 
To evaluate whether the hemodynamic effects of PEA bears any 
relationship to the modulation of RAS, we determined the expression 
of AT1 receptors and ACE in the vasculature from SHR. As shown in 
figure 18, AT1 expression has been found increased both in mesenteric 
bed and carotid in SHR compared with WKY (panel 18A and 18C, 
respectively), whereas it significantly decreased in SHRs treated with 
PEA. Thereafter, we also evaluated the vascular source of Ang II, 
determining ACE protein expression. As shown in figure 18B and 
figure 18D, the increased expression of ACE in both vascular tissues 
of SHR, was blunted by PEA treatment in mesenteric bed and carotid, 
respectively. 
 
Figure 18. Effect of PEA on AT1 and ACE protein expression in mesenteric bed and 
carotid. Representative Western blots show bands in mesenteric bed (A and B) and carotid (C 
and D) of SHR and WKY rats. Data are expressed as means ± SEM. ***P<0.001, **P<0.01 
and *P<0.05 and vs WKY; ###P<0.001 and ##P<0.01 vs SHR. 
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6.3.2. PEA reduces the activation of AT1 pathways in mesenteric bed 
To evaluate the modulation of AT1 activation following PEA 
treatment, we analyzed several signaling pathways downstream this 
receptor, such as NF-κB activation through IκBα degradation, and 
STAT3 and ERK1/2 phosphorylated state. As shown in figure 19, 
PEA treatment partially prevented IκBα degradation (figure 19A), 
reduced the increased phosphorylation of STAT3 (figure 19B) and 
ERK1/2 (figure 19C) in SHRs, attenuating the increase of AT1-
mediated signaling in SHR basal conditions. 
 
Figure 19. Effect of PEA on activation of transcription factors in mesenteric bed and its 
modulation. IκBα (A), pSTAT3/STAT (B), and pERK1/2 (C) immunoblots are shown. Data 
are expressed as means ± SEM. **P<0.01 and *P<0.05 vs WKY; ###P<0.001, ##P<0.01 and 
#P<0.05 vs SHR. 
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7. PEA improves glucose tolerance, insulin sensitivity and 
lipid homeostasis in DIO animals reducing hepatic and 
systemic inflammation 
 
7.2. Effect of PEA on body weight, food intake and fat mass in DIO 
mice 
Consistent with numerous previous studies, the DIO mice gained 
significantly more body weight compared to STD animals throughout 
the experimental period. As shown in figure 20A, a slight steady 
decrease in body weight was evidenced in PEA-treated DIO animals 
during 10 weeks of treatment. However, AUC of body weight during 
time was markedly increased by HFD and significantly reduced by 
PEA treatment (figure 20B). As shown in figure 20C, fat mass, 
measured at the end of the study, was significantly increased in DIO 
animals, compared to STD mice, and reduced by PEA treatment of 
DIO mice. The food intake rates for all animals were measured once a 
week. As shown in figure 20D no difference in food intake, in the 
following 10 weeks, was found between DIO and PEA-treated DIO 
mice. No modification of body weight, fat mass, or food intake were 
recorded in PEA-treated STD mice compared to control STD.  
 
7.3. Effect of PEA on blood pressure 
Since hypertension is an important feature of MetS, we also evaluated 
blood pressure. As shown in figure 21A, DIO mice showed an increase  
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Figure 20. PEA treatment induced body weight, fat mass and food intake modifications 
in diet induced obese mice. Body weight (A) and related AUC (B), fat mass (C) and food 
intake (D) of STD and DIO mice treated or not with PEA are shown. Data are expressed as 
mean ± SEM (n=10 for each group). ***P<0.001 and **P<0.01 vs STD; #P<0.05 vs DIO. 
 
of blood pressure values compared to STD animals detected at 8-th 
week of treatment. PEA-treated mice showed a trend of decrease in 
blood pressure. Conversely, a strong and significant effect on blood 
pressure was shown following PEA treatment of DIO at 9-th week 
compared to DIO mice (figure 21B). 
 
Figure 21. PEA treatment on systolic blood pressure. Panel A shows systolic blood 
pressure values of STD and DIO mice treated with PEA measured at 8-th week. Panels B show 
the systolic blood pressure values at 9-th week of PEA treatment. Data are expressed as mean 
± SEM (n=10 for each group). *P<0.05 vs STD; #P<0.05 vs DIO. 
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7.4. Effect of PEA on serum biochemical parameters 
The effects of the chronic treatment with PEA on biochemical serum 
parameters in mice fed STD or HFD are shown in figure 22. As 
expected, DIO mice showed a significant increase in cholesterol 
(figure 22A), triglycerides (figure 22B), and ALT (figure 22C) levels 
compared to STD animals. The chronic administration of PEA to DIO 
mice led to a strong reduction of all parameters examined. 
 
 
Figure 22. PEA restore serum metabolic parameters. Cholesterol (A), triglycerides (B) and 
ALT (C) serum levels from STD and DIO treated or not with PEA are shown. Data are 
expressed as mean ± SEM (n=10 for each group). ***P<0.001 vs STD; ###P<0.001 and 
##P<0.01 vs DIO. 
 
7.5. PEA restores serum adipokines levels and systemic glucose 
homeostasis 
PEA treatment improves serum adipokines levels and systemic 
glucose homeostasis. Indeed, serum leptin levels, significantly 
increased in DIO mice, were significantly reduced by PEA (figure 
23A). Conversely, DIO animals showed lower levels of adiponectin 
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than STD group, the adipokine levels were normalized by PEA 
treatment (figure 23B). 
 
Figure 23. Effect of PEA on circulating leptin and adiponectin levels. Leptin (A) and 
adiponectin (B) are shown. Adipokine levels were normalized Data are expressed as mean ± 
SEM (n=10 for each group). ***P<0.001 vs STD; ###P<0.001 vs DIO. 
 
Furthermore, compared with STD, DIO mice showed a marked 
increase in fasting glucose and insulin level. PEA prevented glucose 
(figure 24A) and insulin (figure 24B) alterations, improving HOMA-
IR (figure 24C).  
 
Figure 24. Effect of PEA on IR. PEA improves body glucose homeostasis. Fasting glucose 
(A), insulin levels (B) and HOMA-IR (C) were reported. Data are expressed as mean ± SEM 
(n=10 for each group). ***P<0.001 and **P<0.01 vs STD; #P<0.05 vs DIO. 
 
7.6. PEA improves glucose and pyruvate tolerance and insulin 
sensitivity 
One week before sacrifice, oral glucose tolerance (OGTT) and insulin 
tolerance test (ITT) were performed to evaluated glucose metabolism. 
PEA, chronically administered in DIO mice, had a clear euglycemic 
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effect determining a significant decrease in glucose levels at 30 and 60 
minutes after glucose administration (figure 25A). Insulin tolerance 
was also evaluated by measuring glucose levels after systemic 
injection of insulin in 5 hours fasted animals. Our results clearly show 
that PEA-treated animals decreased glucose levels at 60, 90 and 120 
minutes, restoring insulin sensitivity (figure 25B). Regarding pyruvate 
tolerance (PTT), also in this case, an increase in glucose levels was 
observed at 30 and 60 minutes in DIO animals compared to STD mice 
that showed a trend of decrease in DIO mice treated with the PEA 
(figure 25C). 
 
Figure 25. PEA effect on glucose homeostasis. Glucose (A), insulin (B) and pyruvate (C) 
tolerance tests were performed in STD and DIO mice. PEA improves glucose tolerance, 
determining a significant decrease in glucose levels at 30 and 60 minutes after glucose 
administration (A); restores insulin sensitivity decreasing glucose levels at 60, 90 and 120 
minutes (B) and shows a trend of decrease in DIO mice treated with the PEA (C). Data are 
expressed as mean ± SEM (n=10 for each group). ***P<0.001, **P<0.01 and *P<0.05 vs 
STD; ###P < 0.001, ##P<0.01 and #P <0.05 vs DIO. 
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7.7. PEA reduces both hepatic and systemic inflammation 
An important evidence is that obesity is characterized by chronic low 
grade inflammation. The inflammatory mediators induce the inhibition 
of insulin signaling, resulting in IR and hyperglycemia. The strong 
increase of inflammatory cytokines and proteins, as TNF-α, IL-1 and 
MCP-1 in serum (figure 26A, 26B and 26C, respectively) and hepatic 
gene expression of TNF-α and IL-6 (figure 26D and 26E, respectively) 
of obese mice, was significantly reduced by PEA treatment, according 
to its well-known anti-inflammatory activity. Therefore, in animals 
treated with PEA, liver inflammatory damage appears reduced. This 
effect was also associated with a reduction of hepatic triglycerides 
content that was significantly enhanced by DIO feeding (figure 26F). 
 
Figure 26. Effect of PEA on hepatic and systemic inflammation. The expression of pro-
inflammatory cytokines TNF-α (A), IL-1 (B) and MCP-1 (C) were analyzed by ELISA kit in 
serum extracts. The mRNA levels of pro-inflammatory cytokines TNF-α (D) and IL-6 (E) 
were analyzed by real-time PCR in liver extracts. Triglycerides were measured in liver (F). 
Data are expressed as mean ± SEM (n=10 for each group). ***P< 0.001 and *P<0.05 vs STD; 
###P<0.001 and #P< 0.05 vs DIO. 
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7.8. PEA improves glucose and lipid homeostasis 
According with the inflammation, other severe alterations 
demonstrated metabolic impairment and tissue IR in DIO mice. We 
examined AMPK and ACC phosphorylation and the expression of its 
downstream protein, PPAR-α. The evaluation of AMPK/ACC 
pathway activation in liver revealed a reduction in the phosphorylated 
AMPK protein in DIO animals and its downstream substrate ACC that 
were prevented by PEA treatment (figure 27A and 27B), indicating an 
increase in fatty acid oxidation, compromised in obese mice. The basal 
level of hepatic PPAR-α, down-regulated in DIO mice, was restored 
by PEA (figure 27C). 
 
Figure 27. Effect of PEA lipid impairment. The expression of pAMPK/AMPK (A), 
pACC/ACC (B) ratio together PPAR-α expression (C), were analyzed by western blot in liver 
extracts. Data are expressed as mean ± SEM (n=10 for each group). **P<0.01 vs STD; 
###P<0.001 and #P<0.05 vs DIO. 
 
Insulin signaling was evaluated determining the activation of its 
pathway and GLUT expression. We evaluated the phosphorylation of 
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the InsR, that showed a trend of decreased in liver of DIO mice 
compared to that of STD animals (figure 28A). Then, we evaluated the 
effectiveness of insulin signaling through the evaluation of Akt 
phosphorylated state (pAkt) and the expression of GLUT-2. PEA 
treatment restored the phosphorylation of Akt and GLUT-2 expression 
markedly reduced in DIO animals (figure 28B and 28C). To address 
the direct effect of PEA on hepatic insulin-sensitivity, we evaluated 
the modulation of insulin signaling altered by the induction of IR in 
vitro using human HepG2 cells. Here, we have demonstrated that PEA 
increases the phosphorylation of Akt, following hormone stimulation 
in insulin-resistant cells (figure 28D). 
 
Figure 28. Effect of PEA on metabolic impairment and IR. Liver pInsR/InsR (A), 
pAkt/Akt (B) ratio and GLUT-2 expression (C), were evaluated. pAkt/Akt (D) ratio was also 
determined in HepG2 cells after stimulation or not with insulin (100 nM) for 24 hours and 
with or without PEA (0.3, 1 and 3μM). (CON=control cells, INS=insulin resistant cells, and 
INS+PEA=insulin resistant cells treated with PEA). After wash out, all cells were stimulated 
with insulin for 10 minutes. In vivo data are expressed as mean ± SEM (n=10 for each group); 
in vitro data are from triplicate experiments. **P<0.01 vs STD; ##P<0.01 and #P<0.05 vs 
DIO; ##P<0.01 and #P<0.05 vs INS. 
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7.9. Effect of PEA on neuronal activation in the ARC and VMH 
hypothalamic nuclei and in human neuroblastoma cells 
Finally, we studied whether PEA was also able to modulate central 
glucose homeostasis at hypothalamic level. Therefore, we examined 
the ARC and VMH neuronal activation, and c-fos immunostaining 
was performed. In the ARC nucleus of DIO mice, a decrease in c-fos 
labeling was found. Interestingly, in the PEA-treated group, a trend of 
c-fos labeling increase was evidenced (figure 29A). Conversely, in the 
VHM of DIO mice a significant decrease in the neuronal activation 
was shown compared to STD mice. In this case, no differences were 
found between DIO and PEA-treated DIO mice (figure 29B). 
 
        
Figure 29. PEA effect on neuronal activation. Immunostaining for c-fos in the 
hypothalamic arcuate and the ventromedial nuclei from STD and DIO mice, treated with the 
vehicle or PEA. Data are expressed as mean ± SEM (n=10 for each group). **P<0.01 vs 
STD. 
 
The involvement of the hypothalamic control of glucose homeostasis 
by PEA, was confirmed in in vitro experiments, using SH-SY5Y 
neuroblastoma. Indeed, neuronal IR was obtained by a long pre-
treatment of SH-SY5Y with insulin (16 hours). When these cells were 
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re-stimulated with the hormone, they showed a reduction of insulin 
signaling activation, measured as phosphorylated Akt. When insulin-
exposed cells were also treated with PEA (1 μM for 6 hours), the re-
stimulation with insulin (10 minutes) showed a restoration of Akt 
phosphorylation, indicating a recovery of insulin-sensitivity (figure 
30). Taken together, these findings underline that this 
acylethanolamide also displays a central effect on glucose 
homeostasis, reducing neuronal IR. 
 
Figure 30. Effects of PEA on Akt phosphorylation in SH-SY5Y cells pAkt/Akt ratio was 
evaluated in SH-SY5Y by Western blot and densitometric analysis. Data are from triplicate 
experiments. ***P<0.001 vs CON; #P<0.05 vs INS. 
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Discussion and conclusions 
 
PEA prevent endothelial vascular dysfunction and hypertension, 
acting on EETs pathway and RAS in SHR 
In this study, we demonstrated the effect of PEA on SHR in reducing 
hypertension and improving EDHF-mediated vasodilation, by the 
modulation EET hydrolysis and RAS in the vasculature. Besides, 
hypertension is an important feature of MetS. PEA ameliorated 
glucose homeostasis and normalized values of HOMA-IR. In this 
animal model, the main finding was the capability of PEA in 
improving EDHF-mediated vasodilator function induced by 
acetylcholine in pre-constricted mesenteric bed from SHRs. EDHF 
effect is identified by stimulating resistance vessels with Ach in 
presence of NOS and COX inhibitors. So, excluding the contribution 
of NO and prostaglandins, through L-NAME and INDO treatment, we 
highlighted the EDHF contribution in vasodilatation of mesenteric 
bed. Interestingly treatment with PEA restored the EDHF impairment 
observed in SHR. Furthermore, PEA treatment in SHR caused a 
significant improvement not only in EDHF, but also in the endothelial 
dysfunction. In fact, evaluating the tone achieved by adding INDO 
plus L-NAME, the contraction was significantly higher in SHR treated 
with PEA compared with SHR, implying a major contribution of 
endothelial-derived relaxing factors in PEA-treated SHRs. A recent 
clinical study on ocular hypertensive patients showed a decrease in the 
intraocular pressure following three months PEA treatment, improving 
the endothelium-dependent flow-mediated vasodilation compared to 
placebo [235]. EDHF plays a main role in the response to vasoactive 
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substances and regulation of vascular tone at small resistance arteries 
level. Indeed, the mesenteric vascular bed plays an important role in 
maintenance of systemic blood pressure producing vascular resistance 
to develop blood pressure and regulate tissue blood flow. 
EDHF is the predominant endothelium-dependent vasodilator in 
resistance vessels unlike in the large conduit vessels, such as the aorta, 
endothelium-dependent responses are mediated by NO [200]. Thus, 
the role of EDHF in the resistance arteries is important in 
cardiovascular diseases, such as hypertension, diabetes mellitus and 
congestive heart failure [236]. 
SHR experimental model is characterized by a reduction of EET 
plasma levels, a reduction of blood pressure in response to sEH 
inhibition and an increased expression and activity of sEH compared 
to normotensive animals [237, 238]. Consistently, we found an 
impairment of EDHF vasodilation elicited by acetylcholine in 
hypertensive rats. This finding agrees with those reported for 
mesenteric arteries of the SHR [239] and in salt-sensitive hypertensive 
patients [240]. These findings suggested us to hypothesize an 
involvement of EET/DHET metabolites, as EDHF, in blood pressure 
lowering effect of PEA, and we found a significant decrease in sEH in 
vascular tissues in SHR after PEA treatment. We showed a significant 
reduction in sEH expression in the vasculature and in serum 14,15-
DHET in PEA-treated SHR, demonstrating, indirectly, an increase in 
vascular-derived EETs levels. The central role of sEH in the initiation 
and establishment of hypertension has been confirmed by evidence 
showing that treatment with sEH-selective inhibitors in Ang II-infused 
hypertensive rats increases the level of EETs, with related decrease in 
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systolic blood pressure [213]. In the mesenteric artery of aged SHRs, 
EDHF-mediated hyperpolarization and relaxation are severely 
attenuated, but completely restored and even augmented after 
inhibition of the RAS [241, 242]. Thus, we also focused on this 
pathway: in our study, RAS modulation is in agreement with previous 
findings, since SHRs showed an increase in AT1 and ACE expression, 
that was prevented by PEA treatment. Consistently with our findings, 
clinical evidence has demonstrated that the actions of Ang II extend 
far beyond classical actions of RAS, but are also linked to wide array 
of cellular pathways including that of inflammatory processes, as well 
as to endothelial disorders with reduction in endothelium-derived 
relaxing factors [222]. However, in rats, ACE has been shown to be 
the most important enzyme for Ang II formation [243]. Evidence 
indicate that several tissues, including vasculature, contain all 
components of the RAS and are thus capable of producing local Ang II 
[225]. Interestingly, vascular inflammatory response has been shown 
to be more closely related to local than circulating Ang II [244]. 
Therefore, local Ang II appears to be more important in the regulation 
of Ang II-induced inflammation. Interaction between Ang II and sEH 
has been established, in fact, the level of this enzyme in the heart and 
endothelium is upregulated by Ang II in vitro in cultured 
cardiomyocytes and vascular endothelial cells and in vivo in rodent 
models, leading to a reduction of half-life of vasodilating and anti-
inflammatory EETs [245]. Therefore, the attenuation of RAS activity, 
shown by AT1 and ACE down-regulation observed in PEA treated 
rats, could be responsible, at least in part, to the reduced expression of 
sEH found in PEA-treated SHRs. Consistently, we showed an 
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attenuation of key downstream factors of Ang II signaling cascade; in 
particular, PEA treatment increased IκBα content in SHR, 
demonstrating a reduction of NF-κB activation, and a reduction of the 
phosphorylated state of STAT3 and ERK1/2. The damping of AT1-
mediated signaling cascade by PEA indicates the reduction of 
transcription factor activation, leading to the modulation of 
downstream genes, including sEH transcription.  
We demonstrate that long-term treatment with PEA alleviates 
hypertension, by improving EDHF-mediated vasodilatation of arterial 
vessels compromised in SHRs. PEA increased serum half-life of EETs 
and reduces AT1 expression and Ang II synthesis in vascular tissues, 
reducing AT1 downstream pathways. Therefore, this compound, could 
modulate in a concerted way the interaction among Ang II, sEH, and 
EETs. In conclusion, PEA could be a useful tool to cure and prevent 
endothelial vascular dysfunction and hypertension, acting on EETs 
pathway and RAS. 
 
PEA improves glucose tolerance, insulin sensitivity and lipid 
homeostasis in DIO animals 
Here, we demonstrate, for the first time, that repeated administrations 
of PEA improve metabolic impairment induced by HFD in an animal 
model of obesity induced by overnutrition.  
As well known, the risk of developing MetS in human depends on 
synergy of both genetic and environmental factors. Nowadays, this 
multifactorial condition has an alarming rate of prevalence, since 
appropriate experimental animal models mimicking the disease in 
humans are crucial in order to solve the difficulties in evaluating the 
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pathophysiology of MetS in human and define new pharmacological 
and multi-target pharmacological therapies.  
Many researchers have employed different types of HFDs (from 20 
and 60 % of total energy) and the source of the fat component may be 
either plant-derived oils (e.g. corn, safflower or olive oil) or animal-
derived fats (e.g. beef tallow and lard) all used to induce obesity in 
animals [91, 246]. Many studies have also indicated that HFD is 
effective in promoting hyperglycemia, IR, dyslipidemia and increased 
free fatty acids in the blood, either independently or concurrently, and 
assessing the chronic effect of dietary fats with different fat content 
(10, 32 and 45 %) on body adiposity and metabolism in rats [247, 
248]. 
These findings demonstrated that energy intake, weight gain, fat mass, 
plasma glucose, cholesterol, triglycerides, free fatty acids, leptin, and 
insulin levels increased dose-dependently with increased dietary fat. In 
particular, mice fed with 60 % HFD exhibited increased body weight, 
total fat pads, plasma triglyceride, high density lipoproteins (HDL) 
cholesterol, and LDL cholesterol levels [249]. It is also well known 
that the lipid accumulation and consequent inflammation in the liver 
can cause IR [250]. The lipotoxicity hypothesis (overproduction and 
accumulation of triglycerides in non-adipose tissues, such as liver, 
muscle, and pancreas) is the common criteria seen in the effect of 
different diets in the development of MetS [251, 252]. 
The main finding of this study is that PEA treatment prevented the 
impairment of glucose homeostasis and the development of IR in a 
mouse model of MetS. IR, one of the main features of MetS, is 
characterized by a reduction of insulin signaling activation and its 
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inability to produce biological effects on metabolically active tissues 
(liver, fat and skeletal muscle). The insulin receptor, in these tissues, 
becomes insensitive to the hormone and the body responds increasing 
its secretion (hyperinsulinemia). The recovery of systemic and liver 
insulin signaling in “fat over fed mice", following PEA treatment, 
demonstrates drug efficacy in restoring glucose homeostasis.  
Previously, the positive effect of PEA on feeding behavior and body 
weight gain has been evaluated in a model of mild obesity due to 
hypoestrogenism induced by ovariectomy in rat [77]. Conversely, 
here, the effects of PEA were studied in a model of severe obesity 
when the disease and its complications were acclaimed (after 12-th 
week of HFD feeding). Treatment with PEA (for 10 weeks), induced a 
constant and slight time-dependent reduction in body weight, that was 
associated with a significant decrease in fat mass as shown by 
bioelectrical impedance. A significant effect on reducing blood 
pressure was also evidenced after a long period of PEA treatment (at 
9th weeks) in DIO mice. 
The evaluation of glucose tolerance showed that chronic 
administration of PEA in obese mice, promoted a significant reduction 
in glycemia in support of its anti-hyperglycemic and euglycemic 
effect, as also confirmed from ITT. PEA induced an increase of 
insulin-sensitive tissues after intraperitoneal hormone injection, and a 
significant reduction in blood glucose levels at different times 
compared to DIO animals. Pyruvate tolerance supported anti-
hyperglycemic action of PEA, suggesting its modulation of hepatic 
gluconeogenesis. 
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As expected, the intake of HFD induced a clear change in the lipid 
profile, characterized by high cholesterol and elevated triglycerides, 
and fatty liver disease characterized by an increase in transaminase 
levels. PEA attenuated DIO-induced alteration of lipid (both at hepatic 
and systemic level, i.e. triglycerides) and hormonal profile, normalized 
HOMA-IR and liver GLUT-2 expression, reducing IR, liver and 
systemic inflammation. In fact, PEA counteracts adiponectin and 
leptin alterations due to obesity: these adipokines are inversely 
involved in glucose and lipid metabolism, through AMPK activation 
[136, 253]. Our results showed decreased serum leptin levels in PEA-
treated mice, consistently with fat mass reduction and restored serum 
adiponectin levels to those of STD mice, associated to AMPK/ACC 
pathway activation, and fatty acid metabolism in the liver. The 
activation of AMPK exhibits multiple effects, including a reduction in 
inflammation, oxidative stress, IR and an increase in lipid metabolism 
[136, 254]. 
In particular, inflammation is known for its contribution in the IR and 
T2DM [165, 255]. In obese patients, an important role is played by the 
state of systemic inflammation [256-258]: in fact, obese individuals 
show elevated circulating levels of inflammatory markers, both pro-
inflammatory cytokines and acute phase proteins [259, 260]. There are 
two types of proteins involved in inflammation: the pro-inflammatory, 
such as MCP-1, TNF-α, IL-6, IL-8, IL-1, leptin, resistin, and the anti-
inflammatory ones, such as IL-10 [261]. 
In our model, several pro-inflammatory cytokines such as TNF-α, IL-1 
and MCP-1 were significantly elevated in serum of DIO animals 
compared to STD mice, while PEA significantly reduces these levels. 
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These anti-inflammatory effects were confirmed by the evaluation of 
gene expression of TNF-α and IL-6 in liver. A reduction, at hepatic 
level, of inflammatory mediators in animals treated with PEA 
compared to DIO control was found, thus confirming its anti-
inflammatory and hepatoprotective effects. 
Physiologically insulin, in target organs involved in glucose 
metabolism such as liver, adipose tissue and skeletal muscle, binds to 
its transmembrane receptor and promotes its auto-phosphorylation. 
The phosphorylated receptor recruits IRS and increases its activation. 
Phosphorylated IRS activates PI3K and promotes the phosphorylation 
of Akt. The activation of this kinase regulates glucose metabolism 
following two ways: first, promoting the translocation of GLUT from 
the cytoplasm to the membrane mediating the uptake of glucose; 
second, through glycogen synthesis. In case of inflammation, 
cytokines inhibit insulin signaling inducing the degradation of IRS1 
protein, which suppresses signaling pathway PI3K/Akt and 
subsequently suppressing the translocation of GLUT and glycogen 
synthesis, resulting in hyperglycemia and IR.  
Here, we demonstrated that PEA restored phosphorylation of insulin 
receptor, activation of Akt and enhanced GLUT-2 expression. All 
these effects induced an increase of hepatic glucose uptake and 
metabolism, contributing to blood glucose reduction and glucose 
homeostasis. Furthermore, we address the direct effect of PEA on 
hepatocyte insulin sensitivity, demonstrating the reversal of IR in 
insulin stimulated HepG2 cells, through the restoration of hormone 
signaling (pAkt). 
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Recently a review has drawn a parallel between obesity, adipose tissue 
changes, and T2DM development [262]. Based on literature data the 
authors show how glucose homeostasis is changed by adipose tissue 
dysfunction. Adipose tissue dysfunction observed in obesity is 
characterised by adipocyte hypertrophy, macrophage infiltration, 
impaired insulin signaling and IR. In addition, there is a release of 
inflammatory adipokines and an excessive amount of FFA promoting 
ectopic fat deposition and lipotoxicity in muscle, liver and pancreas. 
Recent evidence supports the idea that adipose tissue is not a passive 
energy storage organ but a dynamic endocrine organ, which regulates 
metabolism through a complex adipocyte communication with the 
adjacent microenvironment. Further studies are needed to determine 
how glucose homeostasis is changed by adipose tissue dysfunction and 
if PEA treatment can modulate this relationship enabling new 
pharmacological strategies with the goal of preventing obesity and its 
related disease. 
All these findings indicate that PEA could be a new useful therapeutic 
tool for the treatment of metabolic dysfunctions associated to obesity, 
such as IR and T2DM. Moreover, its anti-inflammatory activity 
represents a further advantage in limiting the low-grade hepatic and 
systemic inflammation often associated to obesity. Future studies are 
needed to investigate the possible combination of PEA with standard 
anti-diabetes drugs, allowing their dose reduction and limiting the 
onset of their adverse effects. 
It is certainly alarming that obesity and its complications can be due to 
fatty acids, as seemingly harmless essential nutrients, but at the same 
time it is very intriguing that a pharmacological use and dosage of an 
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endogenous lipid is able to limit or prevent its progression and to 
restore, at last in part, lipid and glucose homeostasis, showing multi-
and conversing mechanisms of action. 
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